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Abstract 
Neuroblastoma is the most common extra-cranial childhood solid tumour which arises from 
embryonic neural crest cells that fail to undergo a differentiation programme to form mature 
sympathetic neurones. Most children with advanced stage neuroblastoma have a 5-year event 
free survival rate of only 20%. However, the spontaneous differentiation of some early stage 
neuroblastoma into non-malignant gangliomas has prompted the search for agents that can 
induce  neuroblastoma  differentiation.  Peroxisome  proliferator-activated  receptor  gamma 
(PPAR) is a member of the nuclear receptor superfamily of ligand-dependent transcription 
factors which play a major role in adipocyte differentiation and exhibits anticancer activity 
against  a  range  of  tumour  cells  in  vitro.  High  levels  of  PPAR  have  been  shown  to  be 
associated  with  differentiated  neuroblastoma  and  low  levels  of  PPAR  with  poorly 
differentiated tumours. Therefore, the aim of this project is to investigate whether PPAR acts 
as a tumour suppressor gene in neuroblastoma.  Our research shows that overexpression of 
PPAR in the human neuroblastoma cell line SK-N-AS cells inhibited cell growth but had no 
effect on cell viability or the degree of differentiation, suggesting that PPAR may modulate 
cell cycle progression in SK-N-AS neuroblastoma cells. Additionally, we show that PPAR  
strongly represses the DNMT1 promoter activity. This suggests that PPAR may in addition 
to regulating the cell cycle also modulate epigenetic processes within the cell. 3 
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Chapter 1 
1.1. General Introduction 
1.1.1 Cancer 
Cancer causes the death of about 7.9 million people per year according to the most recent 
World Health Organization census (WHO Mortality Database, 2007). Cancer has different 
characteristics involving uncontrolled growth, failure of cell differentiation, metastasis and 
invasion of neighbouring tissues. Metastasis is the process by which cancer cells spread via 
the vasculature system to start tumours in other parts of the body, often involving the adrenal 
medulla, liver, brain or the bones (Lodish et al., 2003). Cancer is caused by genetic damage 
or mutations which affect the regulation of cell growth or apoptosis. Mutations in DNA can 
be inherited or acquired. Acquired mutations occur either spontaneously through errors in 
meiosis or DNA replication or through physical or chemical agents such as radiation, viruses, 
transposons  and  mutagenic  chemicals.  The  major  types  of  mutations/alterations  include 
chromosomal rearrangements, deletions, insertions or point mutations. There are two classes 
of  genes  which  when  mutated  can  lead  to  cancer;  these  are  called  proto-oncogenes  and 
tumour  suppressor  genes  (King  2000).  Proto-oncogenes  are  cellular  genes,  which  mainly 
promote cell growth or cell survival. They can be activated by chromosome translocations, 
gene amplifications or point mutations which results in either overexpression or increased 
activity of the protein product (King 2000). For instance, the MYCN gene, which is involved 
in cell proliferation, has been found to be amplified up to 150 times in neuroblastoma (Ishola 
and Chung 2007, Maris et al 2007). Approximately 100 oncogenes have been identified to 
date (Rang et al., 2003) and these include genes such as Ras, Myc, ERK and tyrosine receptor 
kinases  (TRK).  On  the  other  hand,  the  normal  cell  expresses  proteins  which  inhibit  the 
neoplastic properties of a cell by either restricting cell growth or being involved in DNA 
repair; these are the tumour suppressor genes and approximately 30 of these have been found 
(Rang et al., 2003). Loss of function of a tumour suppressor gene due either to a deletion or 
mutation can also lead to cancer. For example, p53 is a tumour suppressor gene, which plays 
a pivotal role in maintaining genome integrity and is inactivated in over 50% of cancers. 
DNA damage leads to the activation of p53 which acts as a transcription factor (King 2000). 
p53 can bind to the promoter region of specific genes, such as p21
CIP1 (cyclin-dependent 
kinase inhibitor 1) to induce cell cycle arrest. At the same time, p53 can also stimulate repair 11 
 
of  DNA  damage,  by  activating  genes  such  as  growth  arrest  and  DNA-damage  inducible 
(GADD45) (King 2000). However, if DNA has been damaged, then p53 can also induce 
programmed cell death where it inhibits the anti-apoptotic factors, BCL2 and BAX resulting 
cell apoptosis which in turn leads to the accumulation of mutations, rearrangements and an 
increased risk of cancer.  
1.1.2 Regulation of gene expression 
Cancer is a disease of the genome that may be triggered by alterations/mutations in DNA 
which lead to the altered expression or activity of genes. In this section, we will focus on how 
transcriptional regulation of the gene occurs (Lodish et al., 2003). 
 
1.1.2.1 Transcription factors and transcriptional regulation  
We already know that the human body has around 30,000 genes (Pecorino 2005). These are 
encoded by our DNA. A gene can roughly be divided into two parts. One is the regulatory 
region and the other is the coding region. In this section, however, we focus on the regulatory 
region (or promoter region). The regulatory region is where RNA polymerase II, an enzyme 
that transcribes all protein coding genes and miRNA genes, binds and initiates transcription. 
A  typical  RNA  polymerase  II  promoter  region  will  contain  a  TA  rich  sequence  called  a 
TATA box. This is the sequence to which RNA polymerase binds via the transcription factor 
II D (TFIID) to initiate transcription. The TATA box, however, is present in only about 10 to 
15%  of  human  genes.  Some  genes  lack  a  TATA  box  and  instead  have  a  downstream 
promoter element (DPE). The binding of the preinitiation complex (PIC) to either the TATA 
box or DPE elicits only a low level of transcription (Thomas et al., 2006). For higher levels of 
transcription, additional factors called transcription factors bind upstream of the PIC, stabilise 
binding and enhance transcription. The sequences to which these transcription factors bind 
are called upstream sequence regions or are referred to as response elements. Moreover, an 
additional  element  is  often  also  present  in  a  RNA  polymerase  II  promoter.  This  is  the 
enhancer element. It can regulate transcription at a distance and in a position- and orientation-
independent manner. These different types of cis acting elements are however only important 
because of the transcription factors or DNA binding proteins that they bind.  
 12 
 
Transcription factors are that bind to gene promoters and regulate transcription. They contain a 
set  of  independent  protein  modules  or  domains  such  as  DNA-binding  12  domains, 
transcriptional  activation  domains,  dimerisation  domains  and  ligand-binding  domains 
(Thomas et al., 2006). There are a number of different classes of DNA binding domains, 
including the helix-turn-helix motifs, the leucine zipper motif, the helix-loop-helix motif, and 
the zinc finger motif. These domains will be discussed further in section 1.3 (figure 1.1). 
 
 
 
 
 
 
 
 
Figure 1.1. Two functional parts of the gene.  
5’ 3’
Promoter region Start site of 
transcription
Enhancer Coding sequence
mRNA
Protein
5’ 3’
Promoter region Start site of 
transcription
Enhancer Coding sequence
mRNA
Protein
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1.1.3 Epigenetics 
Traditionally  cancer  has  been  seen  as  a  genetic  disease  however  there  is  now  increasing 
evidence that cancer can be caused by both genetic and epigenetic alterations (Esteller 2002). 
Epigenetics is defined as processes that induce heritable changes in gene expression without 
altering the DNA sequence. The main epigenetic mechanisms are DNA methylation, histone 
modification and micro RNAs. 
1.1.4 DNA Methylation 
In 1948 the Hotchkiss group first identified 5-Methylcytosine (m
5C) in DNA; they called this 
DNA methylation. DNA methylation is an action in which a methyl group is added to 5'-
cytosine of DNA. The majority of methylated cytosines are found as part of the dinucleotide 
CpG. CpGs are not randomly distributed throughout the genome but tend to cluster in regions 
at the 5' ends of genes called promoters in areas known as CpG islands. CpG islands are 
defined  as  a  sequence  longer  than  200  base  pairs  with  a  GC  content  of  over  50%,  in  a 
genome-wide average of about 40%  (Takai and Jones 2002). In general hypomethylation is 
associated with transcriptional activation and hypermethylation with transcriptional silencing. 
DNA  methylation  inhibits  transcription  either  by  blocking  transcription  factor  binding  or 
through the binding of methyl CpG binding proteins which in turn recruits histone modifying 
enzymes  to  the  DNA  which  induces  a  closing  down  of  the  chromatin  structure.  DNA 
methylation  is  essential  for  genomic  imprinting,  X  chromosome  inactivation  and  for 
establishing and maintaining tissue-specific patterns of gene expression (Bird 2002).  
DNA methylation is brought about by the DNA methyl transferases of which there are three 
main  types:  DNA  methyl  transferase  1  (DNMT1)  which  is  the  maintenance  methyl 
transferase responsible for copying patterns of methylation from the parental strand of DNA 
onto the newly synthesised strand during replication. DNMT3a and 3b are the de novo forms 
responsible for establishing DNA methylation patterns (Reik et al 2001). DNA methylation is 
largely established during development (Dean et al 2003) and essentially stably maintained 
throughout our life although there is some epigenetic drift in old age which has been linked to 
cancer (Mathers 2003) (figure 1.2).  14 
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Figure 1.2. A. Mechanism of DNA methylation. The methyl group is donated by universal 
methyl donor S-adenosylmethionine (SAM), which is converted to S-adenosylhomocysteine 
(SAH). B. The family of DNMT can be divided into de novo and maintenance. The de novo 
enzymes are DNMT3a and DNMT3b which can create m
5CpG dinucleotides in unmethylated 
DNA and the  maintance enzyme  DNMT1 binds to the  methyl groups to hemimethylated 
DNA during replication. C. Gene silencing can be caused by CpG methylation. The methyl 
group (CH3) is linked to C-G di-nucleotide which usually exists in the promoter region of a 
gene. When the gene is methylated on the CpG island, it can affect the chromatin status of the 
gene and prevent the binding of regulatory factors. D. DNMT1 can recruit the protein methyl 
CpG binding protein 2 (MeCp2), which in turn can recruit histone deacetylases (HDACs) 
which  remove  acetylated  groups  from  the  lysine  of  the  histones  promoting  transcription 
silencing.  16 
 
1.1.5 Histone Modification 
The  DNA  in  our  cells  is  wrapped  around  a  series  of  positively  charged  proteins  called 
histones which interact with the negatively charged DNA in a structure known as chromatin. 
The basic unit of chromatin is a nucleosome. In a nucleosome 146 base pairs of DNA is 
wrapped around a core of eight histone proteins; two molecules of histone 2A, two of histone 
2B, two of histone H3 and two of histone H4. Each nucleosome is then folded upon itself to 
form a solenoid or 30nm fibre which is then further compacted and looped to form a 200nm 
fibre  (Lodish  et  al.,  2003).  There  is  now  substantial  evidence  which  shows  that  post-
translational  modification  of  the  histones  plays  a  key  role  in  regulating  gene  expression. 
Histone proteins have 2 domains-a globular domain and an amino terminal tail domain which 
is rich in lysine residues. Modification of the N-terminal tails of the histones by acetylation, 
methylation, ubiquitination or phosphorylation sets up the histone code which is deciphered 
(Abedin et al 2009) by the readers of the cells which in turn bring about gene activation or 
repression. The most studied histone modifications are histone acetylation and methylation. 
Histone acetylation is brought about by the recruitment of histone acetyl transferases (HATs) 
via activating transcription factors which then acetylate the lysines in N-terminal tails of the 
histones  neutralising  their  positive  charges  leading  to  an  opening-up  of  the  chromatin 
structure  and  gene  activation.  In  contrast  inhibitory  transcription  factors  recruit  histone 
deacetylases  (HDACs)  which  remove  the  acetyl  groups  from  the  histones  restoring  their 
positive charge leading to a closing down of the chromatin and gene repression (Kouzarides 
2007).  Histone  methylation  in  contrast  is  associated  with  both  gene  activation  and  gene 
repression  depending  on  which  lysine  residue  within  the  histone  tail  is  methylated. 
Methylation  of  H3K4  is  associated  with  gene  activation  while  methylation  of  H3K9  is 
associated with gene repression (Kouzarides 2007).  
1.1.6 Epigenetics and Cancer  
It has been demonstrated that the dysregulation of epigenetic processes is a major contributor 
to  human  disease,  such  as  cancer  in  mammals  (Plass  2002). A  change  in  the  epigenetic 
regulation  of  genes  has  been  implicated  as  a  causal  mechanism  in  a  number  of  cancers 
including lung (Li et al 2006), breast cancer and colon cancer as well as urological cancers 
(Krishnan  et  al  2007).  Specifically  increased  cancer  risk  is  associated  with  global 
hypomethylation  of  the  genome  with  concurrent  hypermethylation  of  the  promoters  of 17 
 
tumour  suppressor  genes.  Global  hypomethylation  can  induce  the  activation  of  proto-
oncogenes, loss of imprinting, chromosomal instability and reactivation of transposons, while 
promoter hypermethylation is associated with the inactivation of tumour suppressor genes 
involved in DNA repair, cell cycle control and apoptosis. The mechanism by which global 
hypomethylation is induced is unclear, but may reflect the global decline in DNA methylation 
associated  with  increasing  age  (Ehrlich  2002).  It  has  been  reported  that  a  reduction  in 
DNMT1  activity  has  been  related  to  age  (Lopatina  et  al  2002),  which  may  lead  to  the 
increased expression of oncogenes, such as c-Myc and c-N-ras. Therefore, it appears that 
modulation of DNMT1 activity is a key regulatory step in the induction of tumorigenesis. 
This may be accompanied by methylation de novo of tumour suppressor genes (Lengauer 
2003)  by  increased  DNMT3a  activity  (Hermann  et  al  2004).  Together  these  changes 
represent a shift in the regulation of gene control which, in turn, may predispose the genome 
to further changes in methylation which results ultimately in neoplasia. 
 18 
 
1.1.7 Folic Acid, DNA Methylation and Cancer 
Folate  is  one  of  the  water-soluble  B  vitamins,  needed  for one-carbon  transfer.  However, 
mammals are unable to synthesis folic acid de novo and need to obtain it from their diet or 
from microbial breakdown in the gut. Folate is essential for synthesis of purine nucleotides 
and thymidylate (Duthie 1999) which are required for DNA synthesis and for DNA/histone 
methylation reactions. Folate deficiency therefore can lead to a decrease in intracellular S-
adenosylmethionone (SAM, the universal methyl donor) and alterations in DNA methylation 
(figure 1.3). For instance, it is widely known that liver tumour development is promoted by 
methyl  deficiency.  Wainfain  and  Poirier  reported  that  in  rats  fed  a  methyl-deficient  diet 
(deficient in choline, folic acid and vitamin B2); global DNA hypomethylation was found 
which  was  induced  over  a  very  short  period  of  time.  The  mRNA  expression  of  proto-
oncogenes,  c-myc,  c-foc  and  c-Ha-ras,  increased  but  the  level  of  these  proto-oncogenes 
returned to normal when the rat was  fed the control diet  (Wainfan and Poirier 1992). A 
methyl group deficient diet has also been shown to unregulate DNMTs in rat liver (Steinmetz 
et al 1998, Wainfan et al 1989, Wainfan and Poirier 1992). Age and dietary folate have been 
reported to be determinants of genomic hypomethylation and p16
INK4a hypermethylation in 
mouse colon (Keyes et al 2007). In contrast folate supplementation has been reported to be 
associated with a reduced risk of colorectal, lung, pancreatic, esophageal, stomach, cervix, 
breast, neuroblastoma and leukaemia (Choi and Mason 2002, Kim 1999b). Thus, together, 
these  findings  suggest  a  mechanism  whereby  folate  intake  may  modulate  the  risk  of 
developing cancer through the induction of altered DNA methylation leading to long-term 
stable changes in gene expression. 
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Figure 1.3.  The mechanisms of folic acid deficiency and DNA instability (adapted from 
(Duthie 1999)). 
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1.2 Neuroblastoma 
When  sympathetic  neuroblasts  fail  to  undergo  terminal  differentiation,  this  may  lead  to 
neuroblastoma (Ishola and Chung 2007, Maris et al 2007). Neuroblastoma is the second most 
common cause of lethal cancer in children (Morgenstern et al 2004). Neuroblastoma cells are 
formed from neural crest cells. These cells are involved in the development of the peripheral 
nervous system. The neuroblastoma is a solid and malignant tumour which appears as a lump 
or mass in the abdomen or in the chest, neck or pelvis around the spinal cord (Schwartz et al 
1974). Various image-based and surgery-based systems are used for assigning a disease stage 
(Maris  et  al  2007).  The  four  clinical  neuroblastoma  stages  as  described  by  both  the 
International Neuroblastoma Staging and the Shimada Classification systems (Shimada et al 
1999) are 1, 2A, 2B, 3, 4 and 4S (Special)-Table 1.1 
Table 1.1 Panel: INSS staging system   
Stage  Definition 
1  Localised tumour with complete resection with or without microscopic residual disease; 
typical ipsilateral lymph nodes negative for tumour microscopically.  
2A  Localised tumour with incomplete resection; typical ipsilateral non-adherent lymph 
nodes negative for tumour microscopically. 
2B  Localised tumour with incomplete resection; typical ipsilateral non-adherent lymph 
nodes positive for tumour. Extended contra-lateral lymph nodes should be negative 
microscopically. 
3  Unrespectable unilateral tumour infiltrating across the middle with or without regional 
lymph node involvement; or localised unilateral tumour with contra lateral regional 
lymph node involvement; or midline tumour with bilateral extension by infiltration 
(unrespectable) or by lymph node involvement. 
4a  Any primary tumour with dissemination to distant lymph nodes, bone, bone marrow, 
liver, skin, or other organs (except as defined by stage 4S) 
4S  Localised primary tumour (as defined for stages 1, 2A or 2B), with dissemination limited 
to skin, liver, or bone marrow (limited to infants< one year age) 
(Ishola and Chung 2007, Maris et al 2007). 21 
 
In stage 1, the tumours are found within one area and can be removed by surgery. In stage 
2A, the tumours are found within one area. They can or cannot be removed by surgery. In 
stage 2B, the tumours are frequently found in lymph nodes. In stage 3, the tumours probably 
cannot be removed by surgery and they may have spread to another part of the body. In stage 
4, the tumours have spread to the skin or other parts of the body and also to distant lymph 
nodes. In stage 4S (special in stage 4), the tumour has spread to skin, liver and bone marrow 
and is almost only ever seen in children less than one year old. However, although stage 4S 
neuroblastoma patients have widespread dissemination of disease, they  have a  favourable 
prognosis  and  a  high  rate  of  spontaneous  regression  (Evans  et  al  1971).  Generally,  the 
patients require minimal treatment when they are in 4S stage neuroblastoma. For instance, the 
survival rate of a two year old child approaches around 90% (Nickerson et al 2000); however, 
there  is  a  higher  risk  of  death  in  neonates  who  have  hepatic  involvement  resulting  in 
respiratory, renal or gastrointestinal compromise.  Most 4S patients usually need cytotoxic 
therapy to reduce the tumour burden (Evans et al 1981). Moreover, the biological features of 
most stage 4S tumours have a favourable histology and non-amplified MYCN gene (Goto et 
al  2001).  However,  it  would  be  interesting  to  know  how  and  why  patients  with  4S 
neuroblastoma who undergo spontaneous regression could be of potentially great benefit in 
opening up new therapy for the other stages of neuroblastoma. 
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1.2.1 Gene Aberrations in Neuroblastoma 
There  are  several  genetic  abnormalities  associated  with  neuroblastoma.  Loss  of 
heterozygosity (LOH) is due to a change from a heterozygous to a homozygous state as a 
result  of  mutations  in  the  second  normal  allele  (King  et  al.,  2000).  This  occurs  when 
homologous chromosomes already have one mutated allele which is passed on to the next 
generation However, when the normal gene from one of the allele chromosomes has lost its 
function, there is a high possibility that this will be related to an unfavourable prognosis and 
poor patient outcome in tumour patients (King, 2000). Over 70%  of tumours have observed 
LOH on chromosome 1 which is usually a deletion at the 1p36 region (Brodeur et al 1981, 
Gilbert et al 1982). Deletions in the short arm of chromosome 1p are related to both MYCN 
amplification and advanced disease stage (Maris et al 2007). 
1.2.2 Oncogene Amplification in Neuroblastoma 
Normally, an increase in the gene dosage relies on genetic mechanism of DNA amplification. 
The  normal  developmental  programme  is  associated  with  scheduled  gene  amplification 
(figure 1.4); for instance, the gene in the ovaries of the fruit fly or the actin gene present 
during  myogenesis  in  the  chicken,  where  gene  amplification  occurs  normally.  However, 
unscheduled amplification or sporadic amplification has been found to occur in solid tumours. 
Oncogene  amplification  is  important  in  several  solid  tumours  which  could  reflect  in  the 
genetic instability in solid tumour cells. There are two main types of DNA amplification: 
double  minutes  (DMs)  or  homogenously  staining  regions  (HSR).  DMs  have  a  small 
chromatin  body,  and  the  paired  chromosome-like  structures  lack  a  centromere.  They 
represent  a  form  of  extra-chromosomal  gene  amplification.  When  DM  chromatin  occurs, 
DNA replication  is seriously  flawed  in normal  cells. This can result  in the production of 
many  single  copies  of  genes  in  the  chromosome.  The  DMs  process  is  associated  with 
increased oncogene expression and is associated with a poor prognosis, especially in solid 
tumours,  involving  brain  tumours  and  neuroblastoma  (Bigner  et  al  1990,  Bigner  and 
Vogelstein 1990). HSRs are chromosomal segments with various lengths which are stained 
after  G-banding.  These  types  of  aberration  are  similar  to the  gene  amplification  or  copy 
number gains that we already know about (Biedler and Spengler 1976, Cox et al 1965). The 
features  of  DM  and  HSR  are  very  common  in  neuroblastoma.  A  good  example  of  gene 
amplification in neuroblastoma is the oncogene-MYCN (myc myelocytomatosis viral related 23 
 
oncogene). The sequence of MYCN is localised to DM and HSR and it is the first oncogene 
of clinical significance demonstrated to associate with  neuroblastomas (Bigner et al 1990, 
Bigner  and  Vogelstein  1990).  Moreover,  it  is  also  the  first  one  to  be  associated  with 
aggressively growing tumour phenotypes, while in 4S stage MYCN amplification is rarely 
seen. In neuroblastoma the MYCN gene is frequently amplified by about 140 fold and all 
copies of the amplified gene are transcriptional active, which could explain the reason why 
the expression of MYCN mRNA is found at a high level in many patients. Therefore, it has 
been demonstrated that amplification of MYCN is strongly related with tumorigenesis, with 
tumour progression and poor prognosis in patients of all ages, at all stages of neuroblastoma 
(Ambros et al 1995, Brodeur et al 1984, Perez et al 2000). 
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Figure  1.4.  DNA  amplification.  DNA  amplification  is  increased  by  repeating  DNA 
replication. The recombination can cause tandem arrays of the amplification DNA. It can be 
excised by chromosome form to double minutes. The other chromosome can be integrated 
either  into  the  other  chromosome  or  double  minute  chromosome  and  it  can  become  the 
homogenous staining region.   24 
 
1.2.3 Neuronal Differentiation Markers in Neuroblastoma 
The neurotrophin receptors (NTRK1, NTRK2, and NTRA3 encoded TrkA, TrkB and TrkC) 
and their ligands (NGF, BDNF and neurotrophin-3, respectively) are important factors which 
regulate cell survival, cell growth and differentiation of neural cells. The expression patterns 
of Trks affect the sympathetic nervous system. TrkA is a signalling receptor for the nerve 
growth factor (NGF). TrkB is a receptor for brain neurotropic nerve growth factor (BDNF) 
and neurotrophin 4 (NT4). TrkC is a receptor for Neurotrophin-3 (NT3)  (Schramm et al 2005) 
(figure 1.5A). Schramm and colleagues (2005) have shown that TrkA plays a major role in 
increasing neuronal differentiation to form benign ganglioneuromas. Expression of TrkA is 
strongly  correlated  with  favourable  outcomes  of  neuroblastoma,  as  for  instance  the 
expression of TrkA is related to the differentiation state of the neuroblastoma and the normal 
copy  number  of  MYCN.  Moreover,  low  expression  of  TrkA  is  related  with  a  high  copy 
number of MYCN (Nakagawara et al 1993, Suzuki et al 1993). In contrast, the expression of 
TrkB which promotes neuroblast proliferation is correlated with the phenotype of invasion 
and high-risk disease (Nakagawara et al 1993, Suzuki et al 1993). Furthermore, it has also 
been  found  that  TrkB  is  expressed  on  unfavourable  and  aggressive  neuroblastoma 
(Nakagawara et al 1993, Suzuki et al 1993). Therefore, TrkA and TrkB have been used as 
neuronal differentiation markers in neuroblastoma (Schramm et al 2005) (figure 1.5B). 
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Figure 1.5.  A. Trk receptors and their neutrophin ligands B. The roles of TrkA and TrkB in 
neuroblastoma cells. The signal of TrkA results in cell growth inhibition, differentiation and 
angiogenesis; TrkA with chemotherapy-induced cell apoptosis. In contrast, TrkB activation 
by BDNF leads to cell proliferation, invasion and chemotherapy resistance.  
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1.2.4 Neuroblastoma and Epigenetics 
There is now evidence that epigenetics may play a role in neuroblastoma as well. Alaminos 
and  his  group  has  shown  that  the  promoter  regions  of  caspase-8  (CASP8)  and  tumour 
necrosis factor receptors DR4, DR5, DcR1 and DcR2 are hypermethylated and silenced in 
paediatric  neuroblastoma  (Alaminos  et  al  2004).  Moreover,  Grau’s  group  in  2010 
demonstrated that prognosis of a patient is not only based on patient’s age at diagnosis, the 
tumour stage and MYCN amplification but also can now be classified according to the degree 
of methylation in neuroblastoma. They found that the patient’s survival could be influenced 
by  epigenetic  aberrations:  for  example,  relapse  susceptibility  is  associated  with 
hypermethylation of CASP8 and poor prognosis is associated with the hypermethylation with 
target of methylation-induced silencing (TMS1) and apoptotic protease activating factor 1 
(APAF1) showed a high influence on overall survival of neuroblastoma. They suggested that 
this could be a good prognostic factor of disease progression for simultaneous analysis of 
hypermethylation of APAF1 and TMS1 (Grau et al 2010).  
1.2.5 Micro RNA and Neuroblastoma 
It has been shown that miRNAs can regulate the expression of both tumour suppressor genes 
and proto-oncogenes. In neuroblastoma it has been reported that miRNA-34a acts as a tumour 
suppressor  gene.  miRNA-34a  expression  increases  during  retinoic  acid-induced 
differentiation of the SK-N-BE cell line, whereas E2F3 protein levels decrease. Thus, adding 
to  the  increasing  role  of  miRNAs  in  cancer,  miR-34a  may  act  as  a  suppressor  of 
neuroblastoma tumorgenesis (Welch et al 2007). Das and colleagues have also shown that all-
trans retinoic acid (ATRA) up-regulates miR-152 which targets DNMT1 leading to a down 
regulation  in  DNMT1  expression  and  reducing  cell  invasiveness,  anchorage-independent 
growth and contributing to the differentiated phenotype (Das et al 2010). 27 
 
1.2.6 Conventional Chemotherapy Drugs and Epigenetic Therapy  
1.2.6.1 Chemotherapy Drugs 
Chemotherapy drugs are the most common way to treat cancer. Chemotherapy drugs are used 
as the first line in the treatment of localised disease; their aim is to stop proliferation and kill 
cancer cells (Roger et al., 2000). The function of chemotherapy drugs is to target DNA, RNA 
and protein to interrupt the process of cell division; however they are not cancer cell specific 
and  also  target  normal  dividing  cells.  Many  chemotherapy  drugs  are  used  to  treat 
neuroblastoma, including cisplatin (Pinkerton et al., 1994). These can increase the survival 
rate of patients with advanced neuroblastoma (Pinkerton et al., 1994). Chemotherapy is used 
in neuroblastoma along with other treatments such as surgery, radiotherapy and bone marrow 
transplantation (Morgenstern et al 2004).  
1.2.6.2 The Mechanism of cisplatin and Etoposide 
Cisplatin is one of the most widely used drugs for the treatment of solid tumours in adults and 
children. Cisplatin (cis-Diamminedichloroplatinum (II), CDDP) is an anticancer drug that has 
been used in the treatment of childhood and adult malignancies. Multi-drug therapy which 
includes  cisplatin  is  an  important  component  for  treating  childhood  cancer,  including 
medulloblastoma and neuroblastoma (Jordan and Carmo-Fonseca 2000, Zamble and Lippard 
1995). Cisplatin binds to the guanine and adenine bases in the position of N7 and induces 
cross  links  within  the  DNA.  However,  cellular  damage  may  be  caused  at  a  number  of 
structural levels by cisplatin, although there is a general consensus in the field that genomic 
DNA is the primary site for cisplatin toxicity. This is because cisplatin has been shown to 
cause both intra- and interstrand crosslinking of DNA. The cisplatin adducts that are formed 
in the process both bend and unwind the DNA duplex, resulting in DNA lesions that inhibit 
cell  cycle  progression,  leading  to  cell  death  by  apoptosis.  There  have  been  a  number  of 
reports which suggest that cisplatin action involves the tumour suppressor p53. The DNA 
damage induced by cisplatin leads to the activation of p53 via  ATR (ataxia telangiectasia and 
Rad3-related) kinase (Pabla et al., 2008). Moreover, once p53 has been activated, it also leads 
to the induction of BAX, Noxa and PUMA which can lead to cell apoptosis (King 2000) 
(Siddik 2003). Etoposide is also used to treat advanced neuroblastoma; this is a chemotherapy 
drug which inhibits topoisomerase II (D'Arpa and Liu 1989). Unfortunately, patients often 28 
 
develop  a  resistance  to  etoposide,  especially  in  recurrent  disease.  In  human  therapy,  a 
combination  of  many  drugs  is  often  applied  to  reduce  the  possibility  of  resistance  to 
chemotherapy drugs (D'Arpa and Liu 1989). 
 
                                                           
Cisplatin
DNA damage
ATR
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Figure 1.6. Treatment with cisplatin induced the response of DNA rapidly, which led to the 
activation of ATR and further phosphorylation. It activates Chk2. p53 can be activated by 
either ATR or Chk2. 
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1.2.6.3 DNA Methylation as a Chemoprevention Target  
Epigenetic therapies that target DNA methylation and DNA methyltransferases have recently 
attracted  significant  interest  for  their  use  in  cancer  prevention.  The  DNA  methylation 
inhibitors,  such  as  5-aza-2'-deoxycytidine,  zebularine  (Cheng  et  al  2004),  antisense 
oligonucleotides to DNMT1 (MacLeod and Szyf 1995), and procainamide (Lin et al 2001) 
are capable of reversing aberrant promoter hypermethylation, leading to gene reactivation and 
restoration of cell growth control, apoptosis and DNA repair capacity (Bender et al 1998, 
Herman et al 1998, Murakami et al 1995, Zhu et al 2001). 5-aza-2'-deoxycytidine is a drug 
that targets the epigenome. It is a nucleoside analogue of cytosine. When 5-azacytidine is 
incorporated into DNA, it inhibits DNA methylation and reactivates silenced genes (Jones 
and  Taylor  1980). The  5-aza-2'-deoxycytidine  covalently  binds  to  DNMTs  and  stops the 
activity of enzyme (Cross et al 1997, Jones et al 1998, Nan et al 1997). It has been used 
successfully in the treatment of acute myeloid leukaemia (AML) (Glover and Leyland-Jones 
1987). Rasheed’s (2007) group reported that treatment with the DNA methylation inhibitor, 
5-aza-2'-deoxycytidine,  can  induce  gene  expression  of  p16
INK4a  which  is  often 
hypermethylated  in  neuroblastoma  cells.  Histone  deacetylases  (HDAC)  have  also  been 
recently  used  as  anti  cancer  agents.  HDAC  functions  as  a  regulator  for  cell  growth, 
differentiation, survival and angiogenesis (Bolden et al 2006). Inhibitors of HDACs such as 
Trichostatin A (TSA) have been used as treatment in various clinical trials in cancer patients 
(Rasheed et al 2007).  
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1.3 Nuclear Receptors  
In order to develop safer and more efficient ways to treat neuroblastoma, scientists have been 
trying to understand the different intracellular pathways of proliferation, survival, and cell-
cycle regulation and differentiation that are implicated  in the pathogenesis of the disease 
(Ishola  and  Chung  2007).  For  instance,  in  vitro  studies  suggest  that  Retinoic  acid  (RA), 
which is a vitamin A derivative and a powerful inducer of cellular differentiation and growth 
inhibition in normal and cancer cells may be able to modulate neuroblastoma cell growth 
(Livera et al 2002). RA binds to the nuclear receptors RAR and RXR. Nuclear receptors are a 
super family of proteins which include receptors for classical steroid hormones which act as 
ligand-activated  transcription  factors  and  play  an  important  role  in  normal  physiological 
processes. Nuclear receptors (NRs) include RAR, RXR, PPARs, thyroid hormone receptor 
(TR), vitamin D receptor (VDR) and the steroid receptors, such as the estrogen receptor (ER). 
In total there are 48 known nuclear receptors in the human genome. NRs bind to a variety of 
hydrophobic  ligands,  such  as  steroid  hormones,  fatty  acids,  leukotrienes,  prostaglandins, 
cholesterol derivatives and bile acids. Ligand binding induces a conformational change in the 
receptor allowing the receptor to activate a set of downstream target genes. Despite  very 
encouraging  results  in  vitro  where  retinoic  aicd  was  able  to  very  effectively  inhibit 
neuroblastoma cell growth and induce cell differentiation, in vivo studies revealed that neither 
13-cis-RA  nor  all-trans-RA  had  any  therapeutic  benefit  for  children  with  recurrent  or 
refractory tumour in neuroblastoma (Adamson et al 2007, Finklestein et al 1992). Regardless 
of these observations, research into the benefits of RA still continues. For example, studies 
are ongoing investigating the combination of a synthetic retinoid with other pharmacological 
agents (Garattini et al 2007).  
Given  the  early  promise  of  retinoic  acid,  researchers  then  turned  their  attention  to  other 
nuclear receptors particularly the family of PPARs. Issemann and Green discovered PPARs 
in  1990  when  they  cloned  it  from  mouse  liver.  Subsequently,  PPARs  has  been  found  in 
Xenopus,  rats  and  humans  (Desvergne  and  Wahli  1999,  Sher  et  al  1993).  PPARγ  and 
PPARβ/ʴ were identified first; followed by PPARʱ later on (Desvergne and Wahli 1999, Hihi 
et al 2002, Kliewer et al 1994). PPARs have a tissue-specific distribution (table 2) and can 
regulate gene expression (Tontonoz et al 1994). The PPARs are involved in a number of 
biological  responses,  such  as  adipogenesis,  lipid  homeostasis,  immune  function,  cell 31 
 
proliferation/apoptosis  and  carcinogenesis  (Akiyama  et  al  2005,  Burdick  et  al  2006, 
Desvergne and Wahli 1999, Lee et al 2003, Michalik et al 2004).  
Table 1.2 Tissue expression of PPARs 
  ʱ  β/ʴ  γ 
Adipose tissue    +  + 
Colon      + 
Liver  +     
Heart  +     
Muscle  ++     
Vascular wall      + 
Skin    +   
Brain    +   
Macrophages      + 
Source: modified from Voutsadakis, 2007 
1.3.1 PPARʱ (alpha) 
PPARʱ is a 52 kDa protein which is encoded on chromosome 22q13.31 (Sher et al 1993), 
(Stienstra et al 2007). PPARʱ is expressed in metabolic tissues such as liver, heart, kidney, 
intestinal mucosa and skeletal muscles (Auboeuf et al 1997, Escher and Wahli 2000, Kliewer 
et al 1994, Mandard et al 2004, Schoonjans et al 1996) and is detected in brown fat and the 
immune system involving lung, placenta and smooth muscle tissue (table 2). It regulates fatty 
acid catabolism and inflammatory processes. 32 
 
1.3.2 PPAR β/ʴ (beta/delta) 
PPARβ is a 50 kDa protein which is encoded on chromosome 6p21.2 (Skogsberg et al 2000). 
It  has  been  shown  that  PPARβ/ʴ  is  ubiquitously  expressed  at  low  levels  in  most  tissues 
(Lemberger et al 1996, Mukherjee et al 1997) but it is expressed at high levels in placental 
and skeletal muscle (Mukherjee et al 1997). Recent data suggest that PPARβ/ʴ is a powerful 
metabolic regulator. It has been reported that PPARβ can regulate the expression of acyl-CoA 
synthetase 2 in the brain which is related to basic lipid metabolism (Basu-Modak et al 1999).  
1.3.3 PPARγ (gamma) 
Human PPARγ is located on chromosome 3 and at 3p25. There are three isoforms which are 
PPARγ1, PPARγ2 and PPARγ3; these three isoforms result from different promoter usage 
(Abdelrahman et al 2005, Fajas et al 1998, Greene et al 1995, Zhu et al 1995). PPARγ1 and 
PPARγ3  mRNA  both  encode  the  PPARγ1  protein,  which  is  expressed  in  most  tissues, 
whereas PPARγ2 mRNA encodes the PPARγ2 protein, which is specific to adipocytes and 
contains an additional 28 amino acids at the amino terminus (Abdelrahman et al 2005, Fajas 
et al 1998, Ricote et al 1998). PPARγ2 is expressed exclusively in adipose tissue and plays a 
pivotal role in adipocyte differentiation, lipid storage in the white adipose tissue, and energy 
dissipation in the brown adipose tissue (Barak et al 1999, Chawla et al 1994). PPARγ is 
critical  for  adipocyte  differentiation;  as  it  regulates the  adipocyte-specific  genes,  such  as 
adipocyte  P2  (aP2)  which  is  an  intracellular  lipid-binding  protein,  which  controls  lipid 
storage and metabolism (Heldin and Ostman 1996). It also plays a key role in controlling cell 
proliferation and cell cycle arrest during the differentiation process, as differentiation induced 
by  PPARγ  is  associated  with  a  loss  of  DNA  binding  for  the  growth-related  E2F/DP 
transcription  complex  and  exit  from  the  cell  cycle  at  G1  (Altiok  et  al  1997).  Knockout 
PPARγ mice (deficient) have been shown to have a lack of adipose tissue, while PPARγ +/- 
mice show a decrease in adipose tissue (Kubota et al 1999, Miles et al 2000). In contrast, 
PPARγ1 is expressed in the colon, the immune system (e.g. monocytes and macrophages) 
and other tissues. PPARγ  is  involved  in glucose metabolism through the  improvement of 
insulin sensitivity and represents a potential therapeutic target of type 2 diabetes (Edelman 
2003). Indeed, insulin-sensitising thiazolidinedione (TZD) drugs which are specific activators 
of  PPARγ ligands are currently used very successfully to treat type II diabetes (Zhang et al 
2004).  33 
 
1.3.4 Mechanism of PPARs 
The  PPAR  subtypes  all  function  as  ligand-activated transcription  factors.  In the  classical 
model of PPAR activation, PPARs bind to DNA as heterodimers with the 9-cis retinoic acid 
receptor  RXR.  The  PPAR/RXR  heterodimer  binds  to  DNA  (Tugwood  et  al  1992)  at 
peroxisome proliferator’s response elements (PPREs) which were originally identified in the 
promoter of the acyl coenzyme A (acyl-CoA) oxidase gene. The PPRE comprises two half 
sites of the conserved sequence  AGGTCA with a spacing of one nucleotide called DR-1 
(AGGTCA X AGGTCA) (figure 1.7). However, there is emerging evidence that the optimal 
binding site differs subtly for each PPAR. This subtle difference in binding preference along 
with  differences  in  tissue-specific  expression  may  explain  the  different  functions  of  the 
different PPARs (Palmer et al 1995).  
Activation  of  transcription  through  the  PPARγ/RXR  dimer  is  blocked  by  associated  co-
repressor proteins, such as the nuclear receptor co-repressor (NCoR), histone deacetylases 
(HDAC), and G-protein pathway suppressor 2 (GPS2)  (Xu et al 1999a). The addition of 
ligand  causes  dissociation  of  the  corepressor  proteins  followed  by  the  recruitment  of 
coactivators, such as PPAR coactivator (PGC-1), the histone acetyltransferase p300, and the 
CREB binding protein (CBP). Formation of the PPAR activation complex leads to histone 
modification (e.g. through acetylation) and altered expression of genes involved in fatty acid 
metabolism, lipid homeostasis, and adipocyte differentiation (figure 1.8). However, there is 
also evidence that, as with other nuclear receptors, heat shock proteins (Hsp) may facilitate 
the folding of newly translated PPARs (Sumanasekera et al 2003). The association of PPAR 
with Hsps, and perhaps other proteins, may keep PPAR in the cytoplasm until the appropriate 
ligand binds the PPAR ligand binding domain, leading to protein dissociation and nuclear 
import of PPAR.  34 
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Figure 1.7. Schematic representation of functional domains of PPARγ. The N-terminal 
A/B region contains the putative ligand-independent transactivation domain (AF-1). The C 
region has two zinc fingers and contains the DNA binding domain The D domain is for co-
factor docking. The E/F region contains the ligand binding domain (adapted from (Li et al 
2006, Mansure et al 2009a)). 
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Figure 1.8. Model of PPARγ action. A. The PPARγ receptor and RXR form a heterodimer 
and  bind  the  PPRE  within  the  promoter  of  a  gene.  Without  PPARγ  ligand  binding,  the 
heterodimer  complex  recruits  a  multicomponent  co-repressor  complex.  The  silencing 
mediator  for  retinoid  and  thyroid  hormone  receptors  (SMRT)  interacts  with  the 
multicomponent corepressor complex through PPARγ. The corepressor includes SIN3 and 
HDAC.  B.  Upon  ligand  binding    the  corepressor  complex  is  replaced  by  a  coactivator 
complex which includes SRC, CBP/p300 and P/CAF, which leads to an opening up of the 
chromatin and gene transcription (Zhu et al 1996). C. PPARγ can also repress transcription 
by inhibiting the activities of other transcription factors, such as NFᴋB and AP-1 families 
(ligand-dependent transrepression) (Mansure et al 2009b). 
1.3.5 The Ligands of PPAR  
PPARγ is activated by ligands, which can be divided into two groups - natural ligands and 
exogenous  ligands.  There  are  numerous  natural  ligands  which  include  fatty  acids, 
eicosanoids, components of oxidised low-density lipoproteins and prostaglandins. Short chain 
fatty acids weakly activate PPARs, while polyunsaturated acids bind and activate PPARs 
more effectively (Xu et al 1999b). One of the most important natural ligands is prostaglandin 
J2 derivative (15dPGJ2). 
1.3.5.1 15-deoxy-D12, 14-PGJ2 (15dPGJ2) 
Prostaglandins  (PG)  are  a  group  of  lipids  which  are  derived  from  fatty  acids,  primarily 
arachidonic  acid.  They  are  released  from  membrane  phospholipids  by  the  action  of 
phospholipases.  The  PG  contains  20  carbon  atoms,  including  five  carbon  rings.  The  PG 
functions as a messenger molecule and it is produced by the cells which respond to a variety 
of extrinsic stimuli and regulate cellular growth, differentiation and homeostasis. Arachidonic 
acid  is  first  converted  to  an  unstable  endoperoxide  intermediate  by  cyclooxygenase  to 
arachiphospholipids.  In  addition,  arachiphospholipids  are  converted  into  one  of  several 
related products, such as PGD2, PEG2ʱ, prostacyclin (PGI2), and thromboxane A2. However, 
it  has  been  demonstrated  that  these  products  affect  the  second  messengers  through 
interactions between G protein-coupled receptors (Hirata et al 1994). The cyclooxygenase 
products including PGD2 exist in a variety of tissues and cells. These effect  many biological 37 
 
processes,  such  as  platelet  aggregation,  relaxation  of  vascular  and  nonvascular  smooth 
muscle  and  nerve  cell  function  (Giles  and  Leff  1988).  PGD2  can  quickly  undergo 
dehydration in vivo and in vitro to yield additional, biologically active PGs of the J2 series 
which bind with high affinity to PPARγ (Fitzpatrick and Wynalda 1983, Kikawa et al 1984).  
1.3.5.2 Thiazolidinediones (TZDs) 
The thiazolidinediones (TZD) are a class of anti-diabetic compounds with potent adipogenic 
activity that have been shown to have a high affinity for PPARγ. TZDs include pioglitazone, 
troglitazone and rosiglitazone. They have been used an oral anti-diabetic drug to improve 
insulin sensitivity in type 2 diabetes patients (Seufert et al 2004). Activation of PPARγ by 
TZDs results in a dramatic decrease in the concentration of serum glucose in patients who 
have diabetes. The mechanism by which PPARγ affects insulin sensitivity is unknown, but in 
rat adipose tissue TZDs appear to regulate the expression of target genes through PPARγ, 
such as lipoprotein lipase (LPL). This enzyme is made primarily in adipose tissue and in 
muscle. It plays a critical role in transporting fats and breaking down lipoproteins. When it is 
activated, adipocyte can facilitate the uptake of circulating fatty acid. It also controls glucose 
and lipid metabolism and energy balance; it directs fatty acid away from skeletal muscle by 
stimulating their uptake by the adipose tissue (Dulloo et al 2004). 
1.3.6 PPARγ and Cancer  
There is now much evidence that PPARγ is important in carcinogenesis, such as prostate, 
colon, breast, lung and various haematological cancers (Wang et al 2006b). Several PPARγ 
mutations have been found in a number of cancers. Four different mutations in the PPARγ 
gene have been found in colon cancer cells (Sarraf et al 1999). One of the mutations, in exon 
3  where  a  frame  shift  occurs  producing  a  protein  which  is  inactive  (Sarraf  et  al  1999). 
Furthermore,  PPARγ  mutations,  both  non-sense  and  mis-sense  mutations,  have  also  been 
found  in  the  ligand  binding  domain;  encoded  for  by  exon  5,  they  affect   ligand  binding 
activity which in turn reduces the ability of PPARγ to activate its target genes (Sarraf et al 
1999).  
It  has  also  been  shown  that the treatment  with  PPAR  agonists  inhibits  proliferation  of  a 
variety of cancer cell lines and induces either apoptosis or cellular differentiation (Elstner et 38 
 
al 1998, Rodway et al 2004b, Sarraf et al 1998, Wang et al 2006b). The mechanism of growth 
arrest generally  involves  modulation of the activity and expression of cyclins and cyclin-
dependent kinase (CDKs), resulting in decreased phosphorylation of retinoblastoma protein 
and a lack of E2F mediated gene transcription. Recent reports have demonstrated that cyclin-
dependent kinase inhibitor (CDKI) expression is up-regulated during cell differentiation both 
in vitro and in vivo (Chellappan et al 1998, Harper and Elledge 1996), suggesting that these 
CDKIs may play an universal role in exiting from the cell cycle and/or maintenance of the 
irreversible growth arrest. The CDK inhibitors, which include  p21
CIP1, p18 and p27
KIP1, are 
induced by ligands of PPARγ and cause cell cycle arrest in adipocyte and colon cancer cells 
(Chen and Xu 2005, Morrison and Farmer 1999). PPARγ may play a key role in cell cycle 
arrest as agonists of PPARγ have been shown to induce the CDK inhibitors such as p18, 
p21
CIP1 and p27
KIP1 which are the inhibitors of CDK which block the cyclin/CDK complexes. 
As a result, the phosphorylation of retinoblastoma (RB) protein was inhibited. Therefore, E2F 
will  not be released  from the retinoblastoma protein, which will  lead to cell  cycle arrest 
(Chang and Szabo 2000, Han et al 2004, Lapillonne et al 2003, Wang et al 2006b, Yang et al 
2005,  Yoshizawa  et  al  2002,  Yoshizumi  et  al  2004). Therefore,  activation  of  PPARγ  by 
ligands  has  now  been  shown  to  inhibit  cell  growth  in  many  cancers.  For  instance,  in 
pancreatic  cancer,  the  PPARγ  ligands,  both  glitazones  and  troglitazone,  induce  p21
CIP1 
expression  which  in  turn  affects  cell  cycle  arrest  (Elnemr  et  al  2000).  In  addition,  after 
treating  with  troglitazone,  the  expression  of    p21
CIP1,  p27
KIP1  and  p18  is  induced,  which 
suggests that CDKI leads to a increase in cell cycle arrest in human hepatoma cells (Koga et 
al 2001). Moreover, given their potency in cell culture systems, TZDs have been used more 
recently in several clinical trials treating human malignancies, prostate (Hisatake et al 2000, 
Mueller et al 2000), colon (Kulke et al 2002) and breast cancers (Burstein et al 2003). 39 
 
1.3.7 Clinical Trials 
PPARγ ligands (TZD) have been used for clinical trials in patients, involving liposarcoma, or 
colon or prostate carcinoma (Demetri et al 1999, Mueller et al 2000). It has been shown that, 
when used to treat high grade liposarcomas, troglitazone induces tumour cell differentiation 
in  vivo  (Demetri  et  al  1999).  Differentiation  was  accompanied  by  the  expression  of 
adipocyte-specific genes, involving aP2, adipsin and PPARγ (Demetri et al 1999). In addition, 
it has been shown that in 41 patients (men) who are in phase Π of clinical trials in advanced 
prostate cancer and being treated with troglitazone (Mueller et al 2000), the expression of 
prostate-specific antigen (PSA) was decreased in 20%  of the patients (Mueller et al 2000). 
PSA is a tumour marker to detect prostate cancer which is related to the size of the tumour. In 
conclusion,  troglitazone  can  be  used  to  minimise  tumour  progression  in  vivo.  However, 
rosiglitazone (RGZ), another class of TZD, has not had the same outcome. RGZ did not bring 
about  significant  morphological  changes  or  have  an  effect  on  the  tumour  progression 
(Debrock et al 2003, Smith et al 2004). 
1.3.8 Troglitazone and Cisplatin  
To  improve  the  efficacy  of  TZDs  a  number  of  groups  have  examined  the  effects  of 
combining TZDs with traditional anticancer agents. Reddy’s (2008) group demonstrated that 
PPARγ  ligands  act  synergistically  with  either  platinum-based  chemotherapeutic  agent 
cisplatin or the taxane-platinum to inhibit cell proliferation in NSCLC cells both in vitro and 
in vivo (Reddy et al 2008). Moreover, Hamaguchi’s group in 2010 has demonstrated that 
troglitazone, ciglitazone, RGZ and 15dPGJ2 act in a dose-dependent manner in mesothelioma 
cells (EHMES-10 and MSTO-211H cells), but when combined with cisplatin there was an 
additive inhibition on MPM cell growth when compared to treatment with an individual drug, 
alone (Hamaguchi et al 2010).   40 
 
1.3.9 PPARγ and Neuroblastoma  
There is agreement that PPARγ/ RXR signalling plays an important role in inhibiting cell 
proliferation  and/or  inducing  apoptosis  (Grommes  et  al  2004a).  PPARγ  is  expressed  in 
tumours  of  the  nervous  system,  such  as  astrocytomas,  glioblastomas  and  neuroblastomas 
(Han et al 2001b, Nwankwo and Robbins 2001, Strakova et al 2004). Moreover, Han et al. 
(2001b)  found  that  in  neuroblastoma  tumours  with  a  well-differentiated  phenotype,  high 
levels of PPARγ were expressed, whereas  in undifferentiated tumours very  low  levels of 
PPARγ were found, suggesting that the level of PPARγ may be an important determinant of 
cell differentiation and a potential prognostic marker.  
Activation of PPARγ by both natural and synthetic ligands has also been shown to induce cell 
cycle arrest, apoptosis and/or differentiation. Kim and colleagues (2003) have shown that the 
natural ligand 15dPGJ2 in both SK-N-SH and SK-N-MC cells inhibits cell growth. Following 
treatment with 15dPGJ2 in SK-N-SH and SK-N-MC cells, proapoptotic proteins are increased, 
involving caspase 3 and caspase 9.  Rodway and colleagues (2004) have  also shown that 
15dPGJ2 can inhibit cell growth and induce apoptosis in IMR-32 cells. They also found that 
lysophosphatidic  acid  attenuates  the  degree  of  the  cytotoxic  effects  of  PPARγ  activation 
induced by 15dPGJ2 in neuroblastoma cells.  
Synthetic ligands of PPARγ have also been shown to inhibit neuroblastoma cells in vitro. 
Valentiner  et  al.  (2005)  demonstrated  that  TZD,  including  ciglitazone,  pioglitazone, 
troglitazone and RGZ, inhibited in vitro growth and viability of the human neuroblastoma 
cell lines (SH-SY5Y, SK-N-SH, IMR-32, LAN-5, LAN-1, LS and Kelly) in a dose-dependent 
manner,  showing  considerable  effects  only  at  high  concentrations  of  ligand  (10µM  and 
100µM).  However  in  these  studies  and  in  other  studies  there  is  growing  evidence  that 
15dPGJ2 and the TZD exert many of their anti cancer effects through a PPARγ independent 
pathway, so the exact contribution that PPARγ makes to growth inhibition in neuroblastoma 
cells is unclear. 
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1.4 The aims of our research  
The main aim of this research is to determine whether PPARγ acts as a 
tumour suppressor gene in neuroblastoma cells and the mechanism of its 
action. 
This will be tested by investigating   
1.  whether alterations in the level of PPARγ expression in neuroblastoma cells affects the 
level of  cell growth, viability or differentiation. 
2.  whether agonists of PPARγ can be used alone or in combination with either conventional 
chemotherapy drugs or with methyl donors to inhibit neuroblastoma cell growth. 
3.  whether PPARγ affects the epigenetic status of the cells. 42 
 
Chapter 2 
Material and Methods 
2.1 Materials 
Chemicals were obtained from Sigma-Aldrich (Poole, Dorset UK) unless otherwise stated. 
Tissue culture plastics and cell culture medium were obtained from Invitrogen 
2.2 Methods 
2.2.1 Bacterial growth medium 
2.2.1.1 Luria broth (LB) medium 
 LB medium was made by adding 1000ml of distilled water to 20g of LB. The solution was 
autoclaved under standard conditions. Finally, ampicillin was added to the LB medium to 
make a final concentration of 100µg/ml.  
2.2.1.2 LB agar 
A concentration of 1.5% (w/v) agar was added to the LB medium and autoclaved. Ampicillin 
was added to the LB agar to make a final concentration of 100µg/ml after the LB agar had 
cooled down to 55ºC. 
2.2.2 Glycerol stocks 
A single colony of bacteria was picked from an LB agar or LB
amp plate and inoculated  into 
10ml of LB or LB
amp medium and incubated in a shaking incubator at 37ºC overnight. 500µl 
of overnight culture was mixed at a ratio of 1:1 with sterile glycerol and vortexed gently to 
mix. Glycerol stocks were initially frozen in liquid nitrogen and subsequently stored at -80ºC 
until use.  43 
 
2.2.3 Small scale isolation of plasmid DNA 
A  single  colony  of  DH5ʱ  transformed  with  the  required  plasmid  was  incubated  in  10ml 
LB
amp medium at 37ºC overnight in a shaking incubator. The overnight cultures were then 
centrifuged  at  3000rpm  for  10  minutes  to  harvest the  cells.  The  cell  pellet  was  then  re-
suspended  in  100µl  glucose-Tris  buffer  (1%  glucose,  25mM  Tris  pH  8.0,  10mM 
ethylenediamine tetraacetic acid (EDTA)) and incubated at room temperature for 5 minutes. 
200µl of cell  lysis solution (0.2M NaOH, 1% sodium dodecyl sulphate (SDS)) was then 
added to the suspension, which was inverted twice and placed on ice for 5 minutes. 150µl of 
neutralisation solution (3M Potassium acetate, 11.5% glacial acetic acid) were added to the 
preparation, which was inverted and placed on ice for a further 15 minutes. The samples were 
centrifuged at 12000 rpm for 15 minutes. The supernatant was collected and an equal volume 
of 1:1 phenol: chloroform was added, mixed and centrifuged at 12000 rpm for -5 minutes. 
The top aqueous layer was then transferred to a fresh tube and treated with 10 units of RNase 
A for an hour at 37ºC. An equal volume of 1:1 phenol: chloroform was added, mixed and 
centrifuged. The top layer was then transferred to a clean tube, mixed with sodium acetate 
(3M pH 5.2) and two volumes of ethanol and placed in a -20ºC freezer for 30 minutes to 
precipitate the plasmid DNA. The precipitated plasmid DNA was pelleted by centrifugation 
at 12000 rpm for 10 minutes, air-dried and re-suspended in 40µl of sterile water.  
2.2.4 Large scale isolation of plasmid DNA 
10ml of LB
amp were inoculated with a single colony of DH5ʱ containing the required vector 
and grown in a shaker incubator at 37ºC for 6 hours. These precultures were used to inoculate 
500ml volumes of LB
amp which had been pre-warmed in a shaking incubator at 37ºC prior to 
the addition. These 500ml  LB
amp cultures were incubated  in a shaking  incubator at 37ºC 
overnight. Overnight cultures were centrifuged at 4000 rpm for 20 minutes at 4ºC in Sorvall 
RC-3B centrifuge (Kendro Laboratory Products Limited, Bishop’s Stortford, and Hertforshire, 
UK).  The  pellets  were re-suspended  in  4ml  Sucrose-Tris  buffer  (730mM  sucrose,  50mM 
Tris-HCL (pH 8.0) containing 188,000 Units of lysozyme). The suspensions were placed on 
ice for 15 minutes, then 500mM EDTA pH 8.0 was added to make the final concentration of 
10mM and the suspensions were returned to ice for a further 15 minutes. Three volumes of 
Triton buffer (150mM Tris-HCl pH 8, 187.5mM EDTA, 3% (v/v) Triton X-100) were added 
and  the  samples  were  mixed  and  incubated  on  ice  for  30  minutes  until  lysis  occurred. 44 
 
Samples were centrifuged at 18000 rpm for 1.5 hours at 4ºC in a Beckman J2-21 centrifuge 
(Beckman Coulter Inc., Fullerton, Californa) and the supernatant (lysate) was collected. The 
supernatant  was  made  up  to  500mM  NaCl  (final  concentration)  extracted  with  an  equal 
volume of 1:1 phenol: chloroform and centrifuged at 3000 rpm for 10 minutes. The top layer 
was decanted to a fresh tube and an equal volume of chloroform was added to make a 1:1 mix. 
The preparation was mixed vigorously with the chloroform and centrifuged at 3000 rpm for 
10 minutes. The top layer was collected, to which 10% polyethylene glycol (PEG) was added 
and dissolved at 37ºC. Once the PEG had dissolved the solution was stored at 4ºC overnight. 
Next day the preparation was centrifuged at 12000 rpm for 20 minutes at 4ºC to obtain a 
pellet. The pellet was re-suspended in 500µl 0.1M Tris-HCl (pH 8) and treated with 10 units 
RNase A for an hour at 37ºC. 500µl PEG buffer (33.4mM PEG 6000, 1M NaCl, 1mM EDTA, 
10mM Tris pH 8) was added to the preparation, which was placed on ice for an hour. A pellet 
was obtained by centrifugation at 12000 rpm for 15 minutes and re-suspended in 400µl Tris-
NaCl (10mM Tris-HCl (pH 8), 500mM NaCl). This solution was treated with a further 10 
units of RNase A for 2 hours at 37ºC and extracted twice with an equal volume of 1:1 phenol: 
chloroform.  The  DNA  was  then  ethanol-precipitated,  centrifuged  at  12000  rpm  for  10 
minutes, air-dried in a tissue culture hood and dissolved in 100µl tissue-culture sterile water. 
Plasmid DNA was visualized on 1% agarose gel. Its optical density was measured at 260 nm 
using a spectrophotometer to determine its concentration. 
2.2.5 Preparation of competent cells and transformation 
On day one, a glycerol stock of DH5ʱ Escherichia coli cells was streaked out on to an LB 
plate without antibiotics.  The plate was left overnight at 37ºC. 10ml of LB  medium was 
inoculated with a single colony of DH5ʱ Escherichia coli cells and incubated in a shaking 
incubator at 37ºC overnight. 100µl of overnight culture was added to 10ml of fresh LB. Cells 
were grown at 37ºC for 2~3 hours until their OD 600 reached 0.4 and they were  in the 
exponential  phase  of  growth.  Cells  were  centrifuged  at  3000  rpm  for  10  minutes,  the 
supernatant discarded and the pellet placed on ice. The pellet was re-suspended in 5ml of 
sterile ice-cold 100mM CaCl2 and placed on ice for 30 minutes. Plasmid DNA (50ng) was 
mixed with 100µl of competent cells, which were left on ice for 30 minutes. Cells were heat-
shocked at 42ºC for 1.5 minutes and returned to ice for a further 30 minutes. Cells were 
inoculated by mixing with 400µl of LB and incubating with shaking at 37ºC for 30 minutes. 45 
 
Cells were pelleted at 3000 rpm for 5minutes and re-suspended in 100µl LB, before being 
plated out on LB
amp agar and incubated in a warm room overnight at 37ºC. 
2.2.6 Plasmid DNA  
pcDNA 3.1 is a mammalian expression plasmid from Invitrogen. Human pSG5-PPARγ1 is a 
mammalian  expression  plasmid.  PPREx3-TK-Luc,  PPARγ  dominant  negative  and  rat 
DNMT1-Luc are the reporter expression plasmid (Table 2.1). 
Table 2.1. 
Construct Name  Source  Details of plasmid or construct 
pcDNA 3.1  Invitrogen  Ampicillin and Neomycin resistance genes for 
selection, expression of gene controlled by CMV 
promoter 
pSG5-PPARγ1  Kind gift from Dr. 
R.Evans (Salk Institute, 
San Diego) 
This is an expression vector carrying the  full 
length cDNA of PPARγ (Elbrecht  et al, 1996)  
PPARγ dominant negative  Kind gift from Professor 
V.K. Chatterjee 
(University of 
Cambridge U.K.) 
PPARγ mutant with preserved ligand and DNA 
binding properties, increased corepressor 
recruitment 
PPREx3-TK-Luc  Kind gift from Professor 
Ronald Evans 
(University of California, 
San Diego) 
Luciferase reporter gene under transcriptional 
control of a triple repeat PPAR response element 
(PPRE) 
Rat DNMT1-Luc  Kind gift from Amal 
Alenad (University of 
Southampton, U.K.) 
Luciferase reporter gene under transcriptional 
control.  Ampicillin resistance gene for selection; 
this is useful both in vitro and in vivo 
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2.2.7 Restriction enzyme digestion 
Restriction enzyme digestion was carried out by incubating plasmid DNA (500ng) with 0.5 
units of restriction enzyme in a 1X restriction enzyme digestion buffer. The reaction was 
incubated at 37ºC for an hour and the results analysed by gel electrophoresis.  
2.2.8 Agarose gel electrophoresis 
For separating DNA fragments around 0.1~10 kb, a 1% agarose gel was used. 1g of agarose 
was  mixed  with  100ml  of  1X  TAE  buffer  and  heated  in  a  microwave  until  the  solution 
becomes clear, and it was then cooled down in water bath at 50~55ºC for 10 minutes. At the 
same time, the gel casting tray was prepared by sealing the end of the gel chamber with the 
masking tape. 5µl of ethidium bromide (from a stock solution of 10mg/ml) was added to the 
cooled gel and then poured into the gel tray. When set, the comb and tape was removed and 
the gel placed into the gel tank. 1X TAE buffer was poured into the gel tank to submerge the 
gel to 2~5 mm depth. The DNA to be analysed was mixed with  loading buffer and then 
loaded into the wells and run alongside a DNA ladder (Fisher BioReagents DNA ladder #Cat: 
BP2571-100). Electrophoresis was carried out at 100 volts (V) for an hour and the DNA 
visualised using a UV light box or gel imaging system. 
 
2.2.9 Conventional polymerase chain reaction  
2.2.9.1 p14
ARF for promoter region 
The p14
ARF promoter region was amplified using conventional PCR. The primers used  to 
amplify  the  p14
ARF  promoter  region  were  (forward  5'-
GCCTCGAGTGGGCTAGACACAAAGGACTCG-3'  and  reverse  5'-
GCAAGCTTGCACCCGCCTTCCCTGAGC-3'). 5µl genomic DNA (250ng) was mixed with 
5µl 10X PCR buffer, 7 or 3.5µl 25mM magnesium chloride, 10µl Q-solution, 1.5µl 10mM 
dNTP mix, 0.5µl forward primer (10µM) and 0.5µl reverse primer (10µM). Water was added 
to  make  a  total  volume  with  50µl  (table  2.2).  The  PCR  reaction  was  then  incubated  in 
Omnigene PCR thermocycler (Hybaid, Ashford, UK) for 45 cycles with 0.5µl Hot start Taq 
polymerase (Qiagen, UK). The PCR reaction was shown in Table 2.2. PCR products were run 
on a 1% agarose gel and visualised by UV light. 47 
 
Table  2.2 (a). PCR condition of p14
ARF  
Table  2.2 (b). The condition with different amount of MgCl2 
  Genomic 
DNA 
dNTP  p14
ARF 
(10mM) 
(r) 
p14
ARF 
(10mM) 
(f) 
10X 
buffer 
Q-
solution 
MgCl2 
(25mM) 
Taq  H2O 
Reaction 1  0.4  1.5  0.5  0.5  5  10  7  0.5  24.6 
Reaction 2  0.4  1.5  0.5  0.5  5  10  3.5  0.5  28.1 
 
 
Table 2.2. PCR conditions. 2.2a The tables show the denaturing, annealing and extension 
temperatures  and  times  for  the  PCR  of  p14
ARF  promoter  region.  The  PCR  product  was 
analysed on a 1% agarose gel after 40 cycles. 2.2b. This shows the components of the PCR 
reaction  when  different  concentrations  of  MgCl2was  used  in  order  to  optimise  the  PCR 
conditions.   
2.3.1 RNA extraction 
Total RNA was extracted using TRIZOL
® reagent (Gibco Life Technologies TM, Paisley, 
Scotland). The cell pellet was washed with PBS and then lysed by gentle pipetting up and 
down in 1ml of TRI REAGENT
®. The cells were lysed at room temperature for 10 minutes 
before the addition of 200µl of chloroform. The TRI REAGENT
®-chloroform mix was mixed 
vigorously and incubated at room temperature for 5 minutes and centrifuged at 12000 rpm for 
15 minutes at 4ºC. The aqueous layer was isolated and RNA was precipitated with 500µl of 
isopropyl alcohol. The RNA precipitate was collected by centrifugation at 12000 rpm for 10 
minutes. The RNA pellet was air-dried and re-suspended in 20µl of autoclaved, 0.1% (v/v) 
diethyl pyrocarbonate (DEPC)-treated water and stored at -80ºC. The RNA concentrations 
(µg/µl) were determined by measuring its optical density at 260 nm. 
Gene  Denature   
Annealing 
 
Extension   
No. of 
Cycles  Temp. (ºC)  Time (sec)  Temp. 
(ºC) 
Time 
(sec) 
Temp. 
(ºC)  Time (sec) 
p14
ARF  95  30  57.7~67.6  60  72  60  40 48 
 
2.3.2 Preparation of cDNA for real-time RT-PCR 
Total cellular RNA was used to synthesise cDNA. In order to ensure removal of any possible 
potentially contaminated DNA, the RNA was treated with  a DNase I (Promaga, Cat No. 
M198A). Firstly, 1µg RNA was added  to 1µl  DNase I and 10x DNase I reaction buffer, and 
added nuclease-free water to 100µl and then put  the mixture in the 50µl tube in the PCR 
machine at 37ºC for 30 minutes (DNA digestion) and 65 ºC for 10 minutes (stop reaction).  
Then, the RNA concentrations were determined by measuring its optical density at 260 nm. 
The RNA was then ready to be transcribed to the cDNA.  
1µg RNA (DNA-free) was added to 1µl of 10mM dNTP which includes dATP, dTTP, dCTP 
and dGTP (Promega, Chilworth, UK), and then the mixture was combined with 1µl random 
hexamers  with  90  OD  units  in  0.1%  (v/v)  DEPC  water  (Amersham  Pharmacia  Biotech 
Limited, Little Chalfont, UK), and followed by 0.1% (v/v) DEPC water to a total volume of 
10µl. Following this, this mixture was incubated at 70ºC for 10 minutes and then cooled on 
ice. To this mix, 2µl of 5X Reverse transcriptase buffer, 1 unit of Moloney-Murine Leukemia 
Virus (M-MLV) reverse transcriptase and 0.1% (v/v) DEPC water were added to make a total 
volume  of20µl.  The  final  mixture  was  incubated  at  room  temperature  for  10  minutes  to 
ensure elongation of the random hexamers and subsequently at 37ºC for 50 minutes. It was 
then heated to 80~94ºC to denature the M-MLV reverse transcriptase and stored at -80ºC 
before use.  
2.3.3 Measurement of mRNA expression by real-time RT-PCR 
Measurement of the levels of specific mRNA transcripts was carried out using the primers 
listed (Supplemental Table 2). Total RNA was isolated from SK-N-AS cells. For quantitative 
RT-PCR  reactions,  cDNA  (5µl)  was  mixed  with  12.5µl  of  SYBR  Green  JumpStart  Taq 
Ready Mix (Sigma) and 1µl of each primer (10µM) in a total volume of 25µl. PCR was 
carried out in a real-time PCR cycler® (Bio-Rad). Reactions were performed at 95ºC for 10 
minutes, 40 cycles of 95ºC for 10 seconds, 53ºC to 60ºC for one minute, 95ºC for one minute, 
72ºC for one minute and then finally 72ºC for 10 minutes (each primer set has been described 
in table 2). Quantisation of targets in each sample was accomplished by measuring the cycle 
number (Ct) using the relative expression method. Samples were analysed in duplicate and 49 
 
the  expression  of  the  individual  transcripts  was  normalised  to  the  housekeeping  gene 
(cyclophilin).  
Table 2.3 RT-PCR primers  
 
2.3.4 Preparation of siRNA  
2.3.4.1 Ligation of the siRNA insert  
The siRNA was designed as reported previously (Gan et al., 2008). The sequence of the sense 
strand of PPARγ siRNA was 5'-GCCCTTCACTACTGTTGAC-3'. The detail of this double 
strand insert was shown in figure 3.7B. The 2 strands were annealed by mixing 2μl of each 
oligonucleotide (1ug/ul) with 46μl of annealing buffer (100mM, K-acetate, 30mM, HEPES-
KOH, PH 7.4, 2mM, Mg-acetate) and then incubated at 90°C for 3 minutes, followed by 
37°C for an hour in the PCR machine. Then the product was ready for the next step for 
ligation with the pSilencer vector (digested with EcoR I and Apa I) or stored at -20°C until 
required. 
 
Gene 
Forward primers 
Reverse primers 
Denature 
 
Annealing 
 
Extension   
No. of 
Cycles  Temp. 
(ºC) 
Time 
(sec) 
Temp. 
(ºC) 
Time 
(sec) 
Temp. 
(ºC) 
Time 
(sec) 
PPARγ  5'-TGCAGATTACAAGTATGAC- 
5'-TCGATATCACTGGAGATC-3' 
95  30  53  60  72  60  40 
p14
ARF  5'-TCTAGGGCAGCAGCC-3' 
5'-GGCGCAGTTGGGCTCCGC-3' 
95  10  60  60  72  60  40 
p16
INKʱ  QIAGEN QT00062090  95  10  54.1~60.2  45  72  60  40 
p21
CIP  5'-ACCTGGAGACTCTCAGGGT-3' 
5'-
GCTTCCTCTTGGAGAAGATCA-3' 
95 
 
10  54.1~60.2  45  72  60  40 
Rat 
DNMT1  
QIAGEN QT00493577  95  10  55  45  72  60  40 
Cyclop-
hilin 
5'-TTGGGTCGCGTCTGCTTCGA-
3' 
5'-GCCAGGACCTGTATGCTTCA-
3' 
 
95  10  60  60  72  60  40 50 
 
2.3.4.2 Digestion of pSilencer 1.0-U6  
Apa I and EcoR I restriction enzymes were used to cut the pSilencer 1.0-U6 vector and create 
a directional cloning site. Following digestion, the linearised vector was purified after gel 
electrophoresis  on  a  1%  agarose  gel  using  QIAquick  Gel  Extraction  Kit  (Qiagen,  UK). 
Following  this,  the  purified  vector  was  diluted  to  0.1μg/μl  following  which  is  ready  for 
ligation or transformation for the negative control.  
 
 
2.3.4.3 Digested pSilencer vector with ligated insert for ligation 
The double-stranded siRNA insert was brought to a concentration of 8ng/μl for the ligation. 
Firstly, 1μl of the insert (8ng) was added to 1μl of the linearised vector (100ng), 1μl 10X T4 
DNA Ligase Buffer, 1μl T4 DNA Ligase (T4 DNA ligase) and 5μl Nuclease-Free Water for a 
10μl  ligation  reaction.  The  ligation  reaction  was  then  incubated  at  room  temperature 
overnight. A negative control ligation should be performed with linearised vector alone and 
no  insert.  Finally  the  pSilencer  vector  with  insert  was  ready  for  transformation  on  to 
competent cells (DH5ʱ).  
2.3.5 Preparation of PPARγ ligands 
2.3.5.1 15-deoxy 12, 14 prostaglandin J2 
15-dexoy 12,  14  prostaglandin  J2  (11-oxoprosta-5Z,  12E,  14Z-tetraen-1-oic  acid)  was 
obtained from Cayman Chemicals (Alexis Corporation, Bingham, UK) supplied in methyl 
acetate. Solvent was removed by evaporation under N2 and 15dPGJ2 was re-suspended in 
100µl dimethyl sulfoxide (DMSO). It was diluted at a ratio of 1: 10 with DMSO before use. 
15dPGJ2 could be used at a concentration of 10µM.  
2.3.5.2 Rosiglitazone  
Rosiglitazone was obtained from Cayman chemicals (Alexis Corporation, Bingham, UK) as a 
white solid. Rosiglitazone was dissolved in DMSO to give a stock solution of 100mM, which 
was stored at -20ºC. 51 
 
2.3.6 Cell culture 
The  human  neuroblastoma  cell  lines  SK-N-AS  were  maintained  in  Dulbecco’s  Modified 
Eagle’s  Medium  (DMEM)  containing  10%  (v/v)  fetal  calf  serum  (FCS)  and  100mM 
glutamine, supplemented with 0.1mg/ml penicillin/streptomycin.  Cells were incubated in a 
humidified atmosphere containing 5% (v/v) CO2. SK-N-AS cells are derived from the bone 
marrow of a female patient with neuroblastoma and consist of a single polygonal shaped cell 
(expression  during  human  neuroblastoma-differentiation,  cell  growth  and  differentiation). 
The cells are non-MYCN amplified, S-type, and derived from a bone marrow metastasis. The 
cells do not express the oncogene MYCN or the anti-apoptotic protein BCL2 but appear to 
express NF-kappa-B constitutively (Gatsinzi and Iverfeldt 2011) The cells were passaged by 
incubation  with  1X  Trypsin-EDTA  (500  units  Trypsin,  0.53mM  EDTA)  in  the  37ºC 
incubator for 5~10 minutes until the cells detached from the plate. At this stage, the cells can 
then be passaged for a new generation. The cells then can be passaged for a new generation  
2.3.7 Freezing cells in liquid nitrogen and resuscitation of frozen cells 
After trypsin-EDTA treatment, cells were centrifuged at 1500 rpm  for 5 minutes and the 
culture medium was carefully removed. Cells were re-suspended in 1ml of freezing culture 
medium (10% v/v DMSO in complete medium) and stored on dry ice at -70ºC and frozen 
overnight at -80ºC before being transferred to liquid nitrogen stores. For resuscitation, cells 
were rapidly thawed and diluted in 6ml of complete culture medium. The cells were then 
pelleted at 1000 rpm for 3 minutes and the culture medium decanted off. Cells were then re-
suspended  in  6ml  of  fresh  complete  medium,  transferred  to  a  tissue  culture  flask  and 
incubated at 37 ºC in a humidified  atmosphere containing 5% (v/v) CO2.  
2.3.8 Cell growth and cell count determination 
SK-N-AS cells were seeded at 1x10
5 cells/ml in a 6-well plate and incubated overnight to 
facilitate attachment. Cells were collected by centrifugation and re-suspended in 25µl PBS 
and 25µl 0.4% trypan blue. Four counts were made per treatment per day and an average 
calculated.  Cell  death  (trypan  blue  positive  cells  due to  loss  of  membrane  integrity)  was 
expressed as a percentage of trypan blue negative cells. The SK-N-AS cells were counted by 
hemocytometer and trypan blue was used for detecting dead cells. Cell growth was measured 52 
 
by counting total cell number (white viable cells) per day and cell viability expressed as the 
number of  trypan blue negative cells  and divided by the total cell number (trypan blue white 
and Blue included). 
To  investigate  the  effect  of  PPARγ  on  the  growth,  differentiation  and  viability  of 
neuroblastoma cells, SK-N-AS cells were transfected with either an empty expression vector 
or an expression vector containing the full length cDNA clone of human PPARγ. To confirm 
that the levels of PPARγ mRNA and protein were increased in the cells transfected with the 
expression  vector  containing  the  full-length  clone  of  PPARγ,  RNA  and  protein  were 
extracted from SK-N-AS cells transfected with either the PPARγ expression vector or empty 
expression  vector  24,  48  and  72  hours  after  transfection.  Cells  were  transfected  with 
metafectene has previously been shown to induce very high transfection efficiency in these 
cells  (A  Dawson  unpublished  data).  This  was  confirmed  by  testing  different  ratios  of 
metafectene/ plasmid DNA. The results showed very high transfection efficiency in SK-N-AS 
cells. 
 
2.3.9 Light microscopy 
SK-N-AS cells were observed using a camera  linked to a Leica DM IL microscope (X40 
objective lens) (Leica Microsystems GmbH, Ernst-Leitz-Strasses 17-37 and 35578 Wetzlar). 
2.4 Metafectene transfection of SK-N-AS cultured cells 
2.4.1 6-well plate with metafectene  
This  was  tested  with  the  best  transfected  efficiency  which  was  1µg  DNA  with  4µl 
metafectene reagent in SK-N-AS cells (as can be seen in figure 3.1AB). However, cells were 
plated at 1x10
5 cells per well in 6-well dishes in complete medium and allowed to attach 
overnight. Two tubes were set up per sample: tube A containing 1µg of reporter plasmid 
DNA  and  100µl  serum-free  DMEM  medium;  and  tube  B  containing  4µl  Metafectene® 
(Biontex) and 100µl serum-free DMEM medium. The contents of tube A were added drop-
wise to the contents of tube B to form a translucent precipitate (table 2.4). The precipitate was 
transferred to the cell culture medium and gently agitated, and then incubated for 30 minutes 
at room temperature. Afterwards, 1ml serum-free DMEM was added to 6-well plates and the 53 
 
contents of tube A and B were combined. The cells were incubated at 37ºC for three hours 
when the medium containing the precipitate was removed. The cells were washed and 2ml 
fresh complete medium was added to the cells. The cells were incubated at 37ºC for 24, 48 
and 72 hours.   
 
2.4.2 12-well plate with metafectene 
Cells were plated at 2.5x10
4 cells per well in 12-well dishes in complete medium and allowed 
to attach overnight. Two tubes were set up per sample: tube A containing 300ng of reporter 
plasmid  DNA  and  25µl  serum-free  DMEM  medium;  and  tube  B  containing  1µl 
Metafectene® (Biontex) and 25µl serum-free DMEM medium. The contents of tube A were 
added drop-wise to the contents of tube B to form a translucent precipitate (table 2.4). The 
precipitate was transferred to the cell culture medium and gently agitated, and then incubated 
for 30 minutes at room temperature. Afterwards, 1ml serum-free DMEM was added to 12-
well plates and the contents from tubes A and B were combined. The cells were incubated at 
37ºC for three hours when the medium containing the precipitate was removed. The cells 
were  washed  and  500µl  fresh  complete  medium  was  added  to  the  cells.  The  cells  were 
incubated at 37ºC for 24, 48 and 72 hours.   
Table 2.4 
 
 
 
 
 
Table 2.4. Shows the different ratios of cell numbers, DNA and metafectene for 6-well and 
12-well plates. 
 
 
 
  Cell 
number 
 
Tube A  
 
Tube B  
DNA (ng)  DMEM 
(serum free) 
Metafectene 
(µl) 
DMEM 
(serum free) 
  6-well  1x10
5  1000  100  4  100 
12-well  2.5x10
4  300  25  1  25 54 
 
2.5 Protein assay 
Cell  extracts were assayed for protein content using the bicinchoninc acid (BCA) protein 
assay kit (Pierce, Rockford, Illinois). A standard curve was produced from a series of diluted 
albumin standards which were prepared from a 2mg/ml stock of bovine serum albumin (BSA) 
(in 0.09% saline and 0.05% sodium azide) using lysis buffer as the dilution. The working 
range  of  the  assay  was  20~2000µg/ml.  25µl  of  each  standard  or  unknown  sample  was 
pipetted into a microplate well and then mixed thoroughly with 200µl of the working pipette 
in a microplate of 50 parts BCATM Reagent A and 1 part of BCATM Reagent B (50: 1, 
Reagent A: B). The plate was covered and incubated at 37ºC for 30 minutes, cooled to room 
temperature and then the absorbance of the samples was  measured at 570 nm on a plate 
reader.  
2.6 Western blot  
Cells were lysed in modified radio-immune precipitation assay (RIPA) buffer (50mM Tris-
HCl, pH 7.4, 150 mM NaCl, 1mM EDTA and 1% NP-40). The protein concentration of each 
sample was determined by BCA
TM protein assay kit from Pierce (Lot No. HE103661); 50µg 
of protein was electrophoresed on 12%  SDS-polyacryamide gel using a Bio-Rad  minigel 
apparatus. Proteins from this gel were transferred to a PVDF membrane from Amersham 
Bioscience (Hybond-P membrane, Lot No. RPN303F) and blocked overnight at 4°C with 
10% dried milk powder and 0.02% Tween 20 in PBS. Membranes were incubated at room 
temperature for anhour at room temperature in 10% dried milk powder in phosphate-buffered 
saline and a 1:1000 dilution of PPARγ (Sc-7196) and alpha-actin (A2668) and washed in 
phosphate-buffered  saline  plus  0.2%  Tween  20. Membranes  were  then  incubated  in 
phosphate-buffered saline plus 0.2% Tween 20 containing 10% dried milk powder with a 
1:10000 dilution of goat anti-rabbit antibody coupled to horseradish peroxidase for one hour. 
Immunoreactive bands were then visualised using SuperSignal
®. 
Table 2.5. 
Name  Description 
10% Resolving Gel  4.2ml 4X resolving solution 
5ml H2O 
3.3ml Acrylamide 30% 55 
 
100µl of APS write out  (100mg/1ml) 
10µl TMED (mixed in last) 
Resolving Solution 
 
50ml of 1.5 M Tris pH 8.8 
2ml of 10% SDS 
l H2O to make 200ml in total 
Running Buffer (10X) 
 
144g Glycine (250mM) 
242g Tris-Base (25mM) 
80g SDS (electrophoresis grade) 0.1% (w/v) 
H2O to make up 8L in total 
Blotting Solution  
 
10g Marvel milk 
100ml TBS-0.1% Tween (400ml TBS+0.4ml Tween 20) 
Stacking Gel 
 
2.5ml stacking solution 2X 
850µl Acrylamide 
1.7ml H2O 
50µl APS 
5µl TEMED (mixed in lastlast to mix in) 
Stacking Solution 
 
25ml 1 M Tris-Base pH 6.8 
2 ml 10% SDS 
 H2O to make up 200 ml in total 
Transfer Buffer 
 
200 ml Running buffer 1X 
50 ml Absolute Methanol 
TBS-Tween (pH 7.4) 
 
1.21g Tris-Base 
4g NaCl 
500ml dH2O 
500µl Tween 20 
 
2.7 Luciferase reporter assay 
Luciferase activity in transfected cells was measured using the dual luciferase assay from 
Promega (Promega, Chilworth, UK). In brief, the cells were lysed in passive 1X lysis buffer 
(100µl/per well) and freeze-thawed twice. Cell debris was pelleted and the supernatant was 
transferred  to  a  fresh  tube.  5µl  of  the  supernatant  for  each  sample  was  first  mixed  with 
luciferase assay  reagent   (LAR ) and the firefly luminescence of the sample measured. 
For each sample, the firefly was measured three times in a TD-20/20 luminometer (Turner 
Designs, Sunnyval, California) and an average luminescence was calculated. 56 
 
2.8 Statistics   
For all quantification analysis, at least three independent experiments were performed. The 
significance of differences for paired data was determined using Student's t-test. P-values less 
than 0.05 were considered significant. 57 
 
Chapter 3  
3.1 Introduction 
Neuroblastoma is thought to arise from embryonic neural crest cells which fail to undergo 
differentiation.  The  long-term  survival  of  neuroblastoma  is  very  poor  as  most  children 
present with disseminated disease. It is well known, however, that spontaneous regression 
can occur in patients who are less than one year old (Berthold et al 2003) and hence much 
recent research has focused on understanding the differentiation pathway in neuroblastoma 
and  identifying  agents  that  induce  neuroblastoma  differentiation.  One  potential  target  is 
PPARγ, which has been shown to play a key role in cellular differentiation in a number of 
tissues, including adipocytes and monocytes (Barak et al 1999, Chawla et al 1994). Moreover, 
Han’s group (2001) has shown that levels of PPARγ protein inversely correlate with the stage 
of  neuroblastoma;  high  levels  of  PPARγ  protein  are  found  in  both  primary  stage 
neuroblastoma and well-differentiated phenotypes (Han et al 2001c), while low levels are 
found  in  high  stage  undifferentiated  neuroblastoma.  Moreover,  both  endogenous  and 
synthetic  ligands  of  PPARγ  have  been  shown  to  inhibit  cell  growth  and/or  induce 
differentiation or apoptosis in a wide variety of cancer cell lines, including prostate, colon, 
breast, lung and various hematological cancers (Panigrahy et al 2003, Wang et al 2006a). 
Clinical  trials  of  the  synthetic  TZD  ligand  are  also  ongoing  in  prostate  cancer  patients; 
however,  several  recent  studies  have  shown  that  many  of  the  effects  induced  by  both 
endogenous  ligands,  such  as  15dPGJ2  and  synthetic  ligands  like  TZDs  occur  through 
pathways independent of PPARγ (Cerbone et al 2007). Therefore, the precise role of PPARγ 
in mediating the anti cancer effects of these ligands is unclear at present and whether the level 
of PPARγ present in neuroblastoma cells may play a role in determining the differentiation 
status  of  the  cells.  In  order  then  to  determine  what  role  PPARγ  plays  in  neuroblastoma 
growth and differentiation and whether high levels of PPARγ expression contribute to the 
well differentiated phenotype of neuroblastoma cells, we have investigated the effects of i) 
over-expressing PPARγ and ii) reducing the level of PPARγ in the human neuroblastoma cell 
line SK-N-AS on cell growth, differentiation and viability.  
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3.2 Results 
3.2.1 PPARγ overexpression in SK-N-AS cells  
To  investigate  the  effect  of  PPARγ  on  the  growth,  differentiation  and  viability  of 
neuroblastoma cells, SK-N-AS cells were transfected with either an empty expression vector 
or an expression vector containing the full length cDNA clone of human PPARγ. To confirm 
that the levels of PPARγ mRNA and protein were increased in the cells transfected with the 
expression vector containing the full length clone of PPARγ, RNA and protein were extracted 
from SK-N-AS cells transfected with either the PPARγ expression vector or empty expression 
vector 24, 48 and 72 hours after transfection.  
The detail of the experiments are that, firstly, RNA was collected, reverse transcribed into 
cDNA and analysed using real-time PCR. To ensure equal amounts of RNA were analysed in 
each sample, cDNA samples were initially analysed using the housekeeping gene cyclophilin. 
We found that the level of PPARγ mRNA was significantly increased in the cells which were 
transfected with the PPARγ expression vector compared to cells transfected with the empty 
expression vector (figure 3.1AB). Moreover, in order to determine that the increase in PPARγ 
mRNA corresponded to an increase in PPARγ protein expression, a western blot was carried 
out using an antibody specific for PPARγ (figure 3.1B). This showed that in cells transfected 
with  the  PPARγ  expression  vector  there  was  a  significant  increase  in  PPARγ  protein 
expression compared to cells transfected with the empty expression vector.   
Having  shown  that  PPARγ  mRNA  and  protein  expression  were  increased  in  the  PPARγ 
transfected cells, we also investigated whether the level of PPARγ activity was increased in 
the cells transfected with the PPARγ expression vector. For this, SK-N-AS cells were co-
transfected with a PPARγ reporter plasmid containing a PPRE element upstream of the TK 
promoter which drives expression of the  luciferase reporter gene together with either the 
PPARγ expression vector or the empty expression vector. Cells were then treated with or 
without the PPARγ ligand 15dPGJ2. The results of the transfection showed that there was a 
higher level of luciferase activity in the cells transfected with the PPARγ expression vector 
than in control cells, and that upon 15dPGJ2 treatment, although PPRE activity increased in 
both control and PPARγ transfected cells, the level of PPRE activity was far higher in the 
PPARγ transfected cells compared to controls (figure 3.1C). As an additional control, cells 
were  also  transfected  with  an  expression  vector  containing  a  dominant  negative  PPARγ 59 
 
cDNA. The PPARγ dominant negative plasmid, which is an artificial PPARγ mutant receptor 
(mutated at L468A/E471A on PPARγ), has the ability to bind to the PPRE promoter region 
and bind the co-repressor, but in the presence of ligand does not exchange the co-repressor 
complex for a co-activator complex (Gurnell et al 2000). Transfection of the PPARγ DN 
plasmid reduced the level of PPRE luciferase activity in the transfected cells with or without 
ligand.  Thus,  these  experiments  demonstrate  that  transfection  of  cells  with  the  PPARγ 
expression vector results in a significant increase in PPARγ expression and that the over-
expressed  protein  is  active  and  able  to  bind  to  its  response  element  and  activate  gene 
expression.  60 
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Figure 3.1. Expression PPARγ in SK-N-AS cells over periods of 24, 48 and 72 hours. A. 
SK-N-AS cells were plated out in 6-well dishes at 1x10
5 cells per well and were transfected 
either  with  the  empty  expression  vector  or  with  the  PPARγ  expression  vector.  Reverse 
transcriptase  PCR  was  used  to  detect the  expression  of  PPARγ,  and  cyclophilin  mRNA. 
Samples were run on a 1% agarose gel. The experiment was carried out in duplicate. B. 
Western blot analysis of PPARγ protein expression in PPARγ transfected cells compared to 
control  transfected  cells.  Western  blotting  was  performed  using  a  human  PPARγ-specific 
antibody. Alpha actin was used as a loading control. The negative control lacked the primary 
antibody (PPARγ). C. PPARγ activity is increased in PPARγ transfected cells. SK-N-AS cells 
were transfected with either the PPARγ expression vector or an empty expression  vector 
together  with  the  PPRE  reporter  plasmid  in  the  presence  or  absence  of  10µM  15dPGJ2. 
Luciferase activity was measured after 24 hours and normalised with protein concentration 
(1µg/µl). Statistics were calculated using student’s  t-test. The experiment represents three 
independent experiments ± s.d. 
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3.2.2 PPARγ promotes cell growth inhibition but did not affect cell viability 
Having shown that the PPARγ cells were expressing active protein, and at a higher level than 
control cells, we next investigated the effect of increased levels of PPARγ on the growth, 
viability and differentiation of neuroblastoma cells. To determine whether over-expression of 
PPARγ  has  an  effect  on  cell  growth  and  cell  viability  in  SK-N-AS  cells,  the  cells  were 
transfected  with  either  the  PPARγ  expression  vector  or  control  vector  and  cell  growth 
assessed after 24, 48 and 72 hours. After 24 hours, there was a small decrease in cell numbers 
in the PPARγ transfected cells compared to controls but this was not significant. However, by 
48 hours, there was a significant decrease in cell numbers in the PPARγ transfected cells 
compared  to  controls  (figure  3.2A).  Interestingly,  however,  there  was  no  corresponding 
decrease in cell viability over the same period (figure 3.2B) suggesting that over-expression 
of PPARγ affects cell growth by inducing growth arrest as opposed to affecting cell viability.   
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Figure  3.2.  The  activation  of  PPARγ  leads  to  growth  inhibition.  SK-N-AS  cells  were 
plated out  in  6-well  dishes  at  1x10
5 cells  per  well  and  transfected  with  either  the  empty 
expression vector or PPARγ expression vector. A. Growth curves of vector-transfected and 
PPARγ-transfected cells were determined using a haemocytometer (*P=0.01). Cell growth 
was  measured  by  counting  the  total  number  of  white  viable  cells  per  day.  The  values 
represent the average of three independent experiments. B. Cell viability was calculated by 
dividing the trypan blue negative cells by the total  number of cells  The values produced are 
the  mean  ±  s.d.  of  triplicate  points  from  a  representative  experiment  (n=3),  which  was 
repeated three times with similar results.  
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3.2.3 Increasing the expression  of PPARγ has  no effect on  SK-N-AS cell 
morphology 
Ligand-activated  PPARγ  plays  a  crucial  role  in  adipocyte  and  monocyte/macrophage 
differentiation (Han et al 2001b). Moreover, ligand-activated PPARγ (using 10µM 15dPGJ2) 
induces  cell  differentiation  in  LA-N-5  neuroblastoma  cells  after  10  days.  To  determine 
whether  increasing  levels  of  PPARγ  may  induce  cell  differentiation  in  SK-N-AS  cells, 
transfected cells carrying the PPARγ plasmid were compared to the empty plasmid controls. 
However,  the  examination  of  cells  at  24,  48  and  72  hours  after  transfection  showed  no 
obvious morphological difference in SK-N-AS cells (figure 3.3). 65 
 
 
   
 
 
 
 
 
 
 
Figure 3.3. Effect of PPARγ overexpression on the morphological differentiation of SK-
N-AS  cells.  Cells were plated out in 6-well dishes with 1x10
5 cells per well  in complete 
medium and allowed to attach overnight, then transfected with a PPARγ or empty expression 
vector (1µg). These images are obtained at a magnification of 200X.  
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3.2.4  Overexpression of PPARγ increases expression of p14
ARF 
Given that our experiments have shown that the overexpression of PPARγ decreased cell 
growth but did not affect cell viability in SK-N-AS cells, we next investigated whether the 
decrease in cell growth was accompanied by the induction of the cell cycle inhibitors p14
ARF, 
p16
INK4ʱ and p21
CIP1. 
Using primers specific for p14
ARF, we found that p14
ARF expression was reduced in PPARγ 
cells 24 hours after transfection compared to control cells; however by 48 (*P=0.03) and 72 
hours  after  transfection  there  was  a  large  increase  in  p14
ARF  expression  in  the  PPARγ 
transfected cells compared to the controls. Interestingly, the induction of p14
ARF at 48 and 72 
hours coincides with the time points at which a significant decrease in cell growth was seen 
(figure 3.4). Because of time constraints, however, we were only  be able to conduct this 
experiment twice (n=2). In the future, it would be useful to repeat this experiment in triplicate.  67 
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Figure 3.4. Induction of p14
ARF in PPARγ overexpressing cells. The expression of p14
ARF 
was detected using real-time PCR. SK-N-AS cells were plated out in 6-well dishes at 1x10
5 
cells  per  well  and  were  transfected  either  with  empty  expression  vector  or  with  PPARγ 
expression vector. Real-time PCR analysis was used to detect the expression of PPARγ (n=2), 
with  cyclophilin  as  an  internal  control.  There  was  a  significant  increase  after  48  hours 
(*P=0.03). Results are from two independent experiments done in duplicate.  
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3.2.5 Cloning p14
ARF promoter region in pGEM easy plasmid   
Having  shown  that  p14
ARF  is  induced  in  cells  overexpressing  PRARγ,  we  wanted  to 
determine whether PPARγ can directly  induce  p14
ARF transcription. In p14
ARF, the PPRE 
sequence  AAAATAAGGGGAATAGGGGAGC  was  found  to  be  present  -459  base  pair 
upstream of the transcription start site. To determine whether PPARγ can directly bind and 
regulate the p14
ARF promoter, we attempted to clone the promoter region of p14
ARF into the 
reporter vector pGL3-basic via the TA cloning vector pGEM easy plasmid. The choice of 
p14
ARF  promoter  primers  5'-GCCTCGAGTGGGCTAGACACAAAGGACTCG-3'  and 
reverse  5'-GCAAGCTTGCACCCGCCTTCCCTGAGC-3'  was  done  using  the  Beacon 
software.  The  expected  PCR  product  should  be  809  base  pair  fragment.  Using  human 
genomic DNA as template for PCR, we repeatedly obtained a fragment of >1000 base pair 
despite  optimisation  through  the  use  of  altered  Mg
2+ concentrations  and  the  addition  of 
DMSO (figure 3.5C). However, it may be the case that because the primers are not specific 
enough, they may anneal to the wrong location on the demonic DNA. Therefore, if there had 
been more time available to conduct this experiment, it would have been useful to design 
another primer to done p14
ARF promoter regions.  
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B. 
      
 
   
ATG (+74)
+1
-2280
PPRE
p14ARF
SP1
-459
Ex1
 
 
 
p14
ARF (Genbank AF082338) 
 
               Forward 
AACCGAAAATAAAAATGGGCTAGACACAAAGGACTCGGTGCTTGTCCCAGCCAGGCGCCCTCGGCGACGC 
GGGCAGCTGGGAGGGGAATGGGCGCCCGGACCCAGCTGGGACCCCCGGGTGCGACTCCACCTACCTAGTC 
CGGCGCCAGGCCGGGTCGACAGCTCCGGCAGCGCCAGCGCCGCGCCGTGTCCAGATGTCGCGTCAGAGGC 
GTGCAGCGGTTTAGTTTAATTTCGCTTGTTTTCCAAATCTAGAAGAGGAGCGGAGCGGCTTTTAGTTCAA 
AACTGACATTCAGCCTCCTGATTGGCGGATAGAGCAATGAGATGACCTCGCTTTCCTTTCTTCCTTTTTC 
                                                         Putative PPRE 
ATTTTTAAATAATCTAGTTTGAAGAATGGAAGACTTTCGACGAGGGGAGCCAGGAATAAAATAAGGGGAA 
        -459 
TAGGGGAGCGGGGACGCGAGCAGCACCAGAATCCGCGGGAGCGCGGCTGTTCCTGGTAGGGCCGTGTCAG 
GTGACGGATGTAGCTAGGGGGCGAGCTGCCTGGAGTTGCGTTCCAGGCGTCCGGCCCCTGGGCCGTCACC 
GCGGGGCGCCCGCGCTGAGGGTGGGAAGATGGTGGTGGGGGTGGGGGCGCACACAGGGCGGGAAAGTGGC 
GGTAGGCGGGAGGGAGAGGAACGCGGGCCCTGAGCCGCCCGCGCGCGCGCCTCCCTACGGGCGCCTCCGG                                                                     
                                                                  
CAGCCCTTCCCGCGTGCGCAGGGCTCAGAGCCGTTCCGAGATCTTGGAGGTCCGGGTGGGAGTGGGGGTG 
                                    Reverse 
GGGTGGGGGTGGGGGTGAAGGTGGGGGGCGGGCGCGCTCAGGGAAGGCGGGTGCGCGCCTGCGGGGCGGA 
                                                +1 Transcription start site                                         
GATGGGCAGGGGGCGGTGCGTGGGTCCCAGTCTGCAGTTAAGGGGGCAGGAGTGGCGCTGCTCACCTCTG 
GTGCCAAAGGGCGGCGCAGCGGCTGCCGAGCTC   71 
 
C. 
 
 
 
D. 
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Figure 3.5. The promoter region of p14
ARF. A. Schematic diagram showing the genomic 
location of p14
ARF/p16
INK4ʱ. B. Location of the putative PPRE within the promoter of p14
ARF. 
C. Amplification of the promoter region of p14
ARF using different concentrations of MgCl2 
and different annealing temperatures. D. Purified p14
ARF promoter region product (the size is 
around 1200 base pair).  73 
 
3.2.6 Determining whether the expression of p16
INK4ʱ and p21
CIP1 (mRNA 
level) can be increased by overexpression of PPARγ in SK-N-AS cells 
It has been demonstrated that PPARγ can directly regulate the cell cycle inhibitor p16
INK4ʱ in 
fibroblasts via a PPRE site AGTGTGAAGGAGACAGGACAGTA (Gan et al, 2008). We 
also investigated whether the cell cycle inhibitor p21
CIP1 contained a putative PPRE site using 
MatInspector (http://www.genomatix.de/en/index.html). This predicted a PPARγ binding site 
within  the  p21
CIP1  promoter  sequence  at  CCAGAGTGGGTCAGCGGTGAGCC  (figure 
3.6B). Given that both p16
INK4ʱ and p21
CIP1 contain potential PPRE sequences within the 
promoter  regions  of  these  genes,  and  are  potentially  regulated  by  PPARγ,  we  next 
investigated whether the overexpression of PPARγ in SK-N-AS cells led to an increase in the 
expression (mRNA) of these cell cycle inhibitors. Then, we can determine whether PPARγ 
directly or indirectly regulates the genes  by using site directed  mutagenesis and transient 
transfection assays. 
 
To determine whether the expression (mRNA level) of p16
INK4ʱ or p21
CIP1 is influenced by 
PPARγ, cDNA was made from RNA extracted from SK-N-AS cells (overexpression PPARγ 
in SK-N-AS cells) and amplified with primers specific to p16
INK4ʱ and p21
CIP1 (QIagen). A 
range of annealing temperatures (54.1, 56.4 and 60.2°C) was used to initially determine the 
best conditions for amplification. cDNA was made from RNA extracted from cells grown  
either in 10% serum or in serum-free medium to induce growth arrest (Pecorino 2005) which 
can be a positive control of p16
INK4ʱ and p21
CIP1. This is because without serum included in 
the culture medium, the cell cycle inhibitor, such as p16
INK4ʱ or p21
CIP1, may be increased 
(Pecorino  2005).  However,  multiple  PCR  products  were  consistently  seen  at  all  three 
temperatures tried (figure A.B). 
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A. 
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B. 
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400
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Figure 3.6. Detecting the mRNA expression of p16
INK4ʱ and p21
CIP1 from SK-N-AS cells. 
A/B. Total RNA was isolated from SK-N-AS cells grown either in serum (FCS) or without 
serum for 24 hours. The RNA was then reverse-transcribed into cDNA and amplified with 
specific primers for p16
INK4ʱ and p21
CIP1, using a range of different annealing temperatures. . 
For p16
 INK4ʱ a 92 base pair PCR product was expected and for p21
CIP1 a 79 base pair product. 
.   75 
 
3.2.7  Production  of  a  PPARγ  siRNA  constructs  to  knock  down  PPARγ 
expression 
siRNAs have been proven to be extremely useful for reducing the expression of target genes 
and analysing gene function. To complement the overexpression studies, we also sought to 
decrease the level of PPARγ in neuroblastoma cells to determine the effect on cell growth, 
differentiation and cell viability. To construct a PPARγ siRNA construct, the vector pSilencer 
(figure 3.7C) was digested with EcoRI and ApaI and purified (figure 3.7DEF). The siRNA 
insert  sequence  to  reduce  PPARγ  expression  was  based  upon  the  sequence  previously 
published  in  Gan  et  al.  (2008); this  is  shown  in  figure  3.7B.  This  was  produced  as two 
oligonucleotides which were annealed to give the stem loop structure and EcoRI and ApaI 
cohesive ends. Cloning of this into the pSilencer vector will result in the loss of the Hind III 
site between the EcoRI and ApaI regions (see figure 3.7C). We then aimed to transfect this 
construct into neuroblastoma cells to assess the effect on PPARγ expression, cell proliferation, 
cell viability and differentiation. However, after ligation of the annealed oligonucleotide with 
the cut pSilencer vector and transformation, 20 colonies were picked and the plasmid DNA 
purified. If the insert has been cloned, then the recombinant plasmid should not be digested 
by Hind III (figure 3.7DE). However, the results showed that the plasmids in each case were 
cut by HindIII, suggesting that the siRNA sequence had not been cloned into the pSilencer 
plasmid (figure 3.7F).  76 
 
A. 
PPARγ protein translation region 
                                  +1 translation start site 
GTGTGAATTACAGCAAACCCCTATTCCATGCTGTTATGGGTGAAACTCTGGGAGATTCTCCTATTGACCCAGAAAGCGATTCC
TTCACTGATACACTGTCTGCAAACATATCACAAGAAATGACCATGGTTGACACAGAGATGCCATTCTGGCCCACCAACTTTGG 
                                                         siRNA target site 
GATCAGCTCCGTGGATCTCTCCGTAATGGAAGACCACTCCCACTCCTTTGATATCAAGCCCTTCACTACTGTTGACTTCTCCA
GCATTTCTACTCCACATTACGAAGACATTCCATTCACAAGAACAGATCCAGTGGTTGCAGATTACAAGTATGACCTGAAACTT
CAAGAGTACCAAAGTGCAATCAAAGTGGAGCCTGCATCTCCACCTTATTATTCTGAGAAGACTCAGCTCTACAATAAGCCTCA
TGAAGAGCCTTCCAACTCCCTCATGGCAATTGAATGTCGTGTCTGTGGAGATAAAGCTTCTGGATTTCACTATGGAGTTCATG
CTTGTGAAGGATGCAAGGGTTTCTTCCGGAGAACAATCAGATTGAAGCTTATCTATGACAGATGTGATCTTAACTGTCGGATC
CACAAAAAAAGTAGAAATAAATGTCAGTACTGTCGGTTTCAGAAATGCCTTGCAGTGGGGATGTCTCATAATGCCATCAGGTT
TGGGCGGATGCCACAGGCCGAGAAGGAGAAGCTGTTGGCGGAGATCTCCAGTGATATCGACCAGCTGAATCCAGAGTCCGCTG
ACCTCCGGGCCCTGGCAAAACATTTGTATGACTCATACATAAAGTCCTTCCCGCTGACCAAAGCAAAGGCGAGGGCGATCTTG
ACAGGAAAGACAACAGACAAATCACCATTCGTTATCTATGACATGAATTCCTTAATGATGGGAGAAGATAAAATCAAGTTCAA
ACACATCACCCCCCTGCAGGAGCAGAGCAAAGAGGTGGCCATCCGCATCTTTCAGGGCTGCCAGTTTCGCTCCGTGGAGGCTG
TGCAGGAGATCACAGAGTATGCCAAAAGCATTCCTGGTTTTGTAAATCTTGACTTGAACGACCAAGTAACTCTCCTCAAATAT
GGAGTCCACGAGATCATTTACACAATGCTGGCCTCCTTGATGAATAAAGATGGGGTTCTCATATCCGAGGGCCAAGGCTTCAT
GACAAGGGAGTTTCTAAAGAGCCTGCGAAAGCCTTTTGGTGACTTTATGGAGCCCAAGTTTGAGTTTGCTGTGAAGTTCAATG
CACTGGAATTAGATGACAGCGACTTGGCAATATTTATTGCTGTCATTATTCTCAGTGGAGACCGCCCAGGTTTGCTGAATGTG
AAGCCCATTGAAGACATTCAAGACAACCTGCTACAAGCCCTGGAGCTCCAGCTGAAGCTGAACCACCCTGAGTCCTCACAGCT
GTTTGCCAAGCTGCTCCAGAAAATGACAGACCTCAGACAGATTGTCACGGAACACGTGCAGCTACTGCAGGTGATCAAGAAGA
CGGAGACAGACATGAGTCTTCACCCGCTCCTGCAGGAGATCTACAAGGACTTGTACTAGCAG 
                                                       translation stop codon 
 
 
 
B. 
5’-GCCCTTCACTACTGTTGACTTCAAGAGAGTCAACAGTAGTGAAGGGCTTTTTT-3’
3’-CCGGCGGGAAGTGATGACAACTGAAGTTCTCTCAGTTGTCATCACTTCCCGAAAAAATTAA-5’
Loop Sense Antisense ApaI EcoRI
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F. 
Uncut       Cut       Cut       Cut     Uncut      Cut       Cut       Cut      
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Figure 3.7. Cloning the PPARγ siRNA oligonucleotide into the pSilencer plasmid. A. The 
position of PPARγ siRNA target sequence is shown. B. Annealed primer pairs were chosen 
for production of the PPARγ siRNA; overhangs are included for ease of cloning. C. The map 
of the pSilencer TM 1.0-U6 siRNA expression vector (Ambion). D/E. The pSilencer plasmid 
was cut with EcoRI. EcoR1-digested pSilencer plasmid was further digested with ApaI. The 
cut plasmid DNA was extracted from the gel ready to clone into the pSilencer plasmid. F. 
Restriction eneyme digests analysis of resulting clones. This shows analysis of two clones. 
These plasmids were digested with HindIII to check whether the insert has been cloned into 
the pSilencer plasmid. Neither sample 1 nor sample 2 carries the PPARγ siRNA.  
 79 
 
3.3 Discussion  
PPARγ is a key regulator of adipogenic differentiation and glucose homeostasis (Picard and 
Auwerx  2002).  Agonists  of  PPARγ  have  also  been  shown  to  be  able  to  induce  the 
differentiation of a wide range of cancer cell lines; however, in many cases the induction of 
growth arrest/differentiation was mediated through a PPARγ independent pathway. To assess 
what  role  PPARγ  plays  in  the  induction  of  cell  cycle  arrest  and  differentiation  in 
neuroblastoma cells, SK-N-AS cells were transfected with an expression vector containing a 
full length cDNA of PPARγ. Cells were transfected with metafectene which Andrew Dawson, 
in the lab had previously shown to give a transfection efficiency of around 75% in these cells. 
To ensure equivalent transfection levels in the cells transfected with the control or PPARγ 
vector, a vector with a marker gene such as GFP could also have been used. We found that 
transfection of the PPARγ expression vector into neuroblastoma cells led to an increase in 
PPARγ, mRNA and protein, and increased PPARγ activity compared to cells transfected with 
the empty vector. Having established that the PPARγ transfected cells contain more active 
PPARγ  protein,  we  next  investigated  the  effect  on  cell  growth,  differentiation  and  cell 
viability. In order to ensure that the transfection of the PPARγ expression vector resulted in 
higher PPARγ expression,  real time PCR and western blot were used to detect both mRNA 
and protein level. 
Overexpression of PPARγ in SK-N-AS cells led to a decrease in cell growth. There was no 
effect however on cell viability, suggesting that PPARγ induces a decrease in cell growth not 
through a decrease in cell viability but through a reduction in the rate of cell growth. There 
was  also  no  corresponding  increase  in  the  morphological  differentiation  of  the  cells, 
suggesting  that  PPARγ  primarily  affects  the  growth  of  the  SK-N-AS  cells  (figure  3.2). 
Consistent with this we did observe an increase in the expression of the cell cycle inhibitor 
p14
ARF.  Interestingly,  the  induction  of  p14
ARF  in  the  PPARγ-transfected  cells  was  not 
observed until 48 and 72 hours after transfection (figure 3.4). Indeed a decrease in p14
ARF 
expression was observed 24 hours after transfection. The increase in p14
ARF expression at 48 
and 72 hours did  however  coincide with the decrease observed  in cell growth. It is very 
interesting that the expression of p14
ARF was increased at 48 and 72 hours.  
Interestingly, bioinformatics analysis of the p14
ARF promoter showed that, like p21
CIP1 and 
p16
INK4ʱ, there is a potential PPRE within the p14
ARF promoter, leading to the possibility that 
PPARγ  may  directly  regulate  p14
ARF  expression.  If  PPARγ  did  directly  regulate  p14
ARF 80 
 
expression, one might perhaps expect an increase in p14
ARF expression at an earlier point in 
time. It may be, however, that the effect of fresh medium and serum after the transfection 
overrides  the  effect  of  PPARγ  regulation,  resulting  in  an  initial  decrease  in  p14
ARF  after 
transfection.  
 
To  determine  whether  PPRAγ  had  a  direct  effect  on  p14
ARF  transcription  the  primers 
promoter, part of the failure to detect a suitably sized PCR product may have resulted from 
the formation of primer dimers making it difficult to distinguish the potential amplicon from 
primer dimers. The problem could be circumvented by designing primers further apart in 
order to give a larger product.  Multiple PCR products were consistently seen at all three 
temperatures (figure 3.6AB). However, it may be a possibility that the primers were designed 
by Qiagen, thus giving rise to an amplicon of a very small size. As result, this would make it 
increasingly difficult to distinguish the amplicon from potential primer dimers. Unfortunately, 
because of the difficulty in cloning the promoter region of p14
ARF we were unable to test this; 
but we could do nested PCR. Nested PCR is a strategy whereby two pairs of PCR primers are 
used for a single locus. The first PCR primer’s product can be used for the second PCR 
primer’s product. If the first PCR product is correct, the second PCR product can prove that 
the PCR product overall has more specificity than expected. Moreover, it has demonstrated 
that the endogenous expression of p21
CIP1 is high in SK-N-SH cells (Mergui et al., 2010) and 
in our lab, we already have this cell line. For example, Takita et al. (1998) showed that a 
TGW cell line, which is a human neuroblastoma cell line, can be used as a positive control 
for  p16
INK4ʱ.  These  results  suggest  that  these  two  cell  lines  (SK-N-SH  and  TGW)  can 
potentially be used as positive controls for future experiments.  
 
It has however been demonstrated that PPARγ can directly regulate the cell cycle inhibitor 
p16
INK4ʱ in fibroblasts (Gan et al 2008). Expression of p16
INK4ʱ is induced by activation of 
PPARγ (Gan et al 2008). p16
INK4ʱ and p14
ARF are transcribed from the same gene cyclin-
dependent kinase inhibitor 2A (CDKN2A). The p16
INK4a transcript contains exon 1ʱ/exon 2/3 
while the p14
ARF transcript contains exon 1β and exon 2 of chromosome 9, but p21
CIP1 and 
p14
ARF are transcribed from and controlled by different promoter regions (Quelle et al 1995). 
Interestingly, p16
INK4ʱ is not expressed in 60% of neuroblastoma cell lines (Takita et al 1998) 
and genetic alterations involving the 9p21 chromosomal region (encoding the p16
INK4ʱ gene) 
are common in human cancers, with loss of LOH being correlated with poor prognosis. More 
importantly, expression of exogenous p16
INK4ʱ in neuroblastoma cells dramatically delays the 81 
 
cell  cycle;  and  interestingly,  treating  these  cells  with  5-aza-2-deoxycytidine  which  is  a 
DNMT1 inhibitor, resulted in increased expression of p16
INK4ʱ and reduced cell proliferation, 
suggesting  that  p16
INK4ʱ  expression  is  regulated  by  methylation  in  neuroblastoma  cells 
(Takita et al 1998). 
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Chapter 4 
4.1 Introduction 
Cancer occurs as a result of uncontrolled cell proliferation, a failure to differentiation, and/or 
through  the  development  of  resistance  to  apoptosis.  Many  different  approaches  to  the 
treatment  of  cancer  have  been  tried,  involving  chemotherapy,  radiotherapy  and  hormone 
therapy.  These  agents  inhibit  DNA  replication  and/or  induce  apoptosis  or  necrosis.  For 
instance small cell lung cancer and leukaemia can respond very quickly to  chemotherapy 
drugs (cisplatin and etoposide) which induce apoptosis (Kurup and Hanna 2004). However, 
drug resistance may occur, caused for instance by deregulation of the apoptotic pathways 
(Viktorsson et al 2005). Resistance to standard chemotherapy results in a very poor prognosis, 
such that complete or partial multi- and high-dose treatments that previously gave about a 
44% survival rate, result in a drop to below 23% in relapsed neuroblastoma patients (Chan et 
al 1997). 
The observation however that stage 4S neuroblastoma undergoes spontaneous regression due 
to the differentiation or apoptosis of the cells has led to considerable interest in finding agents 
that induce neuroblastoma differentiation or apoptosis in vivo (Brodeur 2003, Ponthan et al 
2003a,  Ponthan  et  al  2003b).  Ligands  of  PPARγ,  which  have  been  shown  to  induce 
differentiation/apoptosis in a number of cancer cell lines in vitro, have been recently used in a 
series of clinical trials to treat liposarcoma, colon and prostate cancers (Demetri et al 1999, 
Mueller et al 2000), with variable success. PPARγ ligands have also been shown to induce 
growth arrest and/or differentiation or apoptosis in neuroblastoma cells in culture, although 
the exact response appears to be dependent on the genotype of the neuroblastoma cells and 
the  concentration  of  ligand  used,  although  for  different  neuroblastoma  cells,  different 
concentrations are required to elicit the same response (Cerbone et al 2007). 
The aim therefore of this chapter was to test the effect of different concentrations of PPARγ 
ligands  on  the  growth,  differentiation  and  viability  of  SK-N-AS  cells  and  to  determine 
whether  PPARγ  ligands  may,  in  combination  with  conventional  chemotherapy  agents  or 
methylating agents, have a greater effect on growth inhibition than either treatment alone. 83 
 
4.2 Results 
4.2.1  The  effects  of  rosiglitazone,  a  synthetic  PPARγ  agonist  on 
neuroblastoma cells in vitro 
In  order  to  determine  the  effect  of  RGZ,  a  synthetic  PPARγ  agonist  on  the  growth  and 
viability of SK-N-AS cells, the cells were treated with increasing concentrations of the PPARγ 
ligand RGZ (5~100µM) and the effect on cell growth determined over a 72 hours time period. 
The results showed that after 24 hours there was no difference in cell number in cells treated 
with 5 or 50µM RGZ, but at 100µM, the total cell number was decreased by 23% (figure 
4.1A).  After  48  hours  of  treatment,  no  difference  in  cell  number  was  seen  at  any 
concentrations of RGZ used, while after 72 hours a decrease in cell number was seen at 5, 50 
and 100µM RGZ. At the highest concentration (100µM), the final cell number was reduced 
to 64% (P=0.001) of the control level after 72 hours. 
In terms of cell viability, after 24 hours of treatment no effect on cell viability was seen apart 
from in samples treated with 100µM RGZ where a small decrease in cell viability was seen. 
After 48 hours, there was no difference in cell viability at any concentration of RGZ, while 
after 72 hours a decrease in cell viability was observed only at the highest concentration of 
RGZ, where cell viability was decreased by 15% (figure 4.1B). 
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Figure 4.1. Time- and dose-dependent effect of rosiglitazone on SK-N-AS cell growth 
and viability. A/B. SK-N-AS cells were plated out in 6-well dishes at 1x10
5 cells per well and 
treated with either a vehicle control (DMSO) or increasing concentrations of RGZ (5~100µM) 
and the effects on cell growth (A) and cell viability (B) were measured over 24, 48 and 72 
hours. Trypan blue was used to distinguish between live (white) and dead (blue) cells. Data 
are expressed as mean ± s.d. of two independent experiments. Denotes a significance of **P< 
0.001 compared with the untreated cells.  85 
 
4.2.2 The effect of combining rosiglitazone and conventional chemotherapy 
agents on SK-N-AS cells 
4.2.2.1 The effect of cisplatin and etoposide on SK-N-AS cells 
In order to determine whether treating neuroblastoma cells with a combination of PPARγ 
agonists and conventional chemotherapy agents might improve potency and allow a reduction 
in  the  concentration  of  conventional  agents,  we  initially  studied  the  effect  of  increasing 
concentrations of cisplatin and etoposide on neuroblastoma cells. 
SK-N-AS cells were treated with either 0, 0.5, 0.75, 1.5 or 7.5µM cisplatin or 0, 0.1, 0.25, 0.5, 
1, 1.5 and 2µM etoposide for 24 and 72 hours, and the effect on cell growth and viability 
analysed.  These  concentrations  of  cisplatin  and  etoposide  had  previously  been  shown  to 
induce growth arrest and cell death in a range of cancer cell lines. After 24 hours, there was a 
trend towards decreased cell growth at all concentrations used, with a significant decrease in 
cell numbers at 7.5µM (P=0.03) of cisplatin (figure 4.2A). However, no significant decrease 
in cell viability was seen at these concentrations. After 72 hours, there was again a trend 
towards  decreased  cell  growth  at  all  concentrations  of  cisplatin  used,  with  a  significant 
decrease in cell growth at 7.5µM (P=0.08) cisplatin. However, no significant decrease in cell 
viability at any of the concentrations was observed (figure 4.2B).  
 
The addition of increasing concentrations of etoposide to SK-N-AS cells showed no change in 
cell growth after 24 hours of treatment with any of the concentrations of etoposide used 
(figure 4.2C). After 72 hours, however, a significant decrease in cell growth was seen at 
1.5µM  (P=0.05)  etoposide.  There  was  however  very  little  effect  on  cell  viability  at  any 
concentration or at any time point (figure 4.2D).  86 
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Figure 4.2. The effect of chemotherapy drugs, cisplatin and etoposide, on the cell growth 
and cell viability of SK-N-AS cells. SK-N-AS cells were plated out in 6-well dishes at 1x10
5 
cells  and  treated  with  either  a  vehicle  control  (DMSO)  or  increasing  concentrations  of 
cisplatin (0.5~7.5µM) and etoposide (0.1~2µM), and the effect on cell growth. (A/C) and cell 
viability  (B/D)  was  measured  over  24  and  72  hours.  Values  represent  the  mean  of  four 
experiments ± s.d. A Student’s t-test was used to analyse the data; * P <0.05 when compared 
with the untreated cells. 
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4.2.2.2 Interaction of rosiglitazone and conventional chemotherapy agents 
leads to an increase in growth inhibition in SK-N-AS cells 
Conventional chemotherapy drugs interfere with DNA replication and affect not only cancer 
cells but also rapidly dividing normal cells, giving rise to a range of side effects (Rang, 2003). 
Therefore,  we  combined  cisplatin  and  etoposide  with  RGZ  to  determine  whether  the 
combination of agents might improve potency and allow a lower concentration of drugs to be 
used.  SK-N-AS  cells  were  treated  with  100µM  RGZ,  the  concentration  at  which  we  had 
consistently  seen  a  reduction  in  cell  growth,  together  with  1  or  5µM  cisplatin  (these 
concentrations of cisplatin  had  been  shown previously to induce a small decrease  in cell 
growth for 72 hours) and the effect on cell growth and viability measured. We found that as 
observed previously the addition of 1 and 5µM cisplatin alone decreased cell growth (figure 
4.3).  Similarly,  in  the  presence  of  100µM  RGZ  alone,  there  was  also  a  decrease  in  cell 
numbers (figure 4.3). When a combination of RGZ and cisplatin (1µM) was used there was a 
29% decrease in cell numbers compared to when cisplatin was used at this concentration 
alone; however at 5µM cisplatin, no additive effect of RGZ was seen. Neither cisplatin alone 
or in combination with RGZ had any effect on cell viability (figure 4.3A). 
When etoposide (0.5, 1.5 and 2µM) was combined with 100µM  RGZ, there were a 34% 
(0.5µM etoposide + RGZ), a 43% (1.5µM etoposide + RGZ) and a 2% (2µM etoposide + 
RGZ)  decrease  in  cell  number  compared  to  cells  treated  with  etoposide  alone.  The 
combination of etoposide at all concentrations used and RGZ also induced a decrease in cell 
viability compared to cells treated with etoposide alone (figure 4.3B). 89 
 
 
Figure  4.3.  The  effect  of  cisplatin  and  etoposide  with  rosiglitazone  on  SK-N-AS  cell 
growth over 72 hours. A/B (i). SK-N-AS cells were plated out in 6-well dishes seeded with 
1x10
5 cells and treated with either a vehicle control (DMSO) or 100µM RGZ together with 
either cisplatin or etoposide at the concentrations indicated. The effect on cell growth was 
measured over 72 hours. Values represent the mean ± s.d. of two independent experiments. 
A/B (ii). The graph shows the average percentage of SK-N-AS cell viability, as observed by 
trypan blue exclusion, of two independent experiments. Statistical analysis was carried out by 
Student’s t-test to identify significant differences between samples.  
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4.2.3 PPARγ ligands and DNA methylating agents 
Aberrant DNA methylation has been associated with the initiation and progression of cancer 
(Plass 2002). Folate is a methyl donor which has been shown to play a very important role in 
the body, as it is essential for DNA synthesis and DNA methylation (Rang, 2003). It has been 
demonstrated  that  the  concentration  of  folate  is  normally  1  to  10ng/ml  in  plasma 
physiologically (Hernandez-Blazquez et al 2000). Low folate supply has been shown in many 
papers to be associated with carcinomas, such as cervical, lung, essophagal, pancreatic (Choi 
and Mason 2000) and breast (Zhang et al 1999). Maternal folic acid intake has also been 
reported  to  decrease  the  risk  of  several  childhood  cancers  (Kim  1999a),  including 
neuroblastoma (French et al 2003b). The recent fortification of flour with folic acid in the 
USA for the prevention of neural tube defects has also been associated with a reduction in 
neuroblastoma by 60% (French et al 2003b). However, the relationship between folic acid 
intake and cancer risk is complex as high levels of folic acid have been also associated with 
an increased risk of colon and breast cancer (Lu and Low 2002). 
To determine therefore whether altering the methylation status of the cells might affect the 
response of neuroblastoma cells to PPARγ ligands, we treated SK-N-AS cells initially with 
increasing  concentrations  of  folic  acid  and  then  in  combination  with  either  RGZ  or 
conventional chemotherapy agents.   
SK-N-AS cells were treated with increasing concentrations of folic acid (1, 5 and 50µM) and 
the  effect  on  cell  growth  and  viability  was  analysed.  The  results  showed  there  was  an 
unsignificant trend towards decreased cell growth in the folic acid-treated cells 24 hours after 
treatment. However, after 48 or 72 hours, no effect was seen. There was no effect on cell 
viability at either 24, 48 or 72 hours after folic acid treatment (figure 4.4AB).  
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Figure 4.4. Graph showing the cell numbers after treating with different concentrations 
of folic acid over 24, 48 and 72 hours. SK-N-AS cells were plated out in 6-well dishes at 
1x10
5 cells and treated with either a vehicle control (DMSO) or increasing concentrations of 
folic acid  (1~50µM) and the effects on cell growth and cell viability were measured over 72 
hours. Trypan blue was used to distinguish between live and dead cells. The values represent 
the mean ± s. d. of two independent experiments.  92 
 
4.2.4 Rosiglitazone and folic acid does not have a significant effect on cell 
growth in SK-N-AS cells 
Rosiglitazone  reduces  neuroblastoma  cell  proliferation,  while  folic  acid  modifies  the 
methylation status of genes (French et al 2003b); therefore, we would like to know whether 
combining RGZ and folic acid affected the response of the cells to RGZ. The results showed 
that in the presence of 1µM folic acid combined with 50µM RGZ, cell numbers decreased by 
7%  although  this  was  not  statistically  significant,  and  by  21%  with  folic  acid  and  RGZ 
(100µM) compared to cells treated with RGZ alone after 24 hours. No effect of folic acid on 
RGZ treatment was seen at other points in time (figure 4.5).    93 
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Figure 4.5. The effect of folic acid and rosiglitazone on SK-N-AS cells. A(i) B(i) C(i). SK-
N-AS cells were plated out in 6-well dishes at 1x10
5 cells and treated with either a vehicle 
control (DMSO) or increasing concentrations of RGZ (50~100µM) with 1µM folic acid, and 
the effect on cell growth and cell viability was measured over 48 hours. Values represent the 
mean ± s.d of two independent experiments. Statistical analysis was carried out by Student’s 
t-test to identify significant differences between samples. 95 
 
4.2.5 The effects of cisplatin and folic acid on neuroblastoma cells   
To determine whether the response of cells to cisplatin would be altered by the presence of 
folic acid, cisplatin (1µM and 5µM) was combined with folic acid and the effect on cell 
growth and viability assessed. However, the results show there is not a significant affect on  
either cell growth or cell viability after combining 1µM folic acid and 1µM or 5µM cisplatin 
over 24, 48 and 72 hours, respectively (figure 4.6ABC). 96 
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Figure 4.6. Graph showing the SK-N-AS cell numbers after treating with folic acid as a 
control, and folic acid and cisplatin in combination over 24, 48 and 72 hours. A(i) B(i) 
C(i). SK-N-AS cells were plated out in 6-well dishes at 1x10
5 cell and treated with either a 
vehicle control (DMSO) or increasing concentrations of cisplatin (1~5µM) with 1µM folic 
acid and the effects on cell growth and cell viability were measured over 24 hours. Trypan 
blue was used to distinguish between live and dead cells using a haemocytometer (n=2). The 
experiment was replicated twice  independently. The values produced are the  mean ± s.d. 
Cells were counted four times. A(ii) B(ii) C(ii). The graph shows the average percentage of 
SK-N-AS cell viability, as observed by trypan blue exclusion, of two independent experiments. 
Cells were counted four times at each concentration and averaged in each experiment. Error 
bars signify one standard deviation from the mean. Statistical analysis was carried out by 
student’s t-test to identify significant differences between samples.  
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4.3 Discussion  
There  is  now  strong  evidence  that  PPARγ  ligands  can  inhibit  neuroblastoma  cell  growth 
(Krieger-Hinck  et  al  2010,  Valentiner  et  al  2005).  In our  group,  Rodway  and  colleagues 
(2004) showed that PPARʱ agonist WY-14643 had no effect on the cell growth of the IMR-
32 neuroblastoma cell line, whereas 15dPGJ2, a PPARγ ligand, inhibited cell growth in the 
same neuroblastoma cells by inducing a G2/M arrest and autophagy. This was mediated only 
partly through a PPARγ dependent pathway. In the laboratory, Andrew Dawson (unpublished 
data) further showed that RGZ and ciglitazone  also inhibited the growth of a  number of 
neuroblastoma  cell  lines  including  IMR-32,  SK-N-AS  and  Kelly  cells,  although  the 
concentration required to induce 50% growth inhibition differed widely depending on the cell 
line, with 5µM RGZ required to induce 50% growth inhibition in IMR-32 and Kelly cells and 
100µM in SK-N-AS cells. Cellai and colleagues (2006) have also demonstrated that RGZ can 
significantly inhibit cell adhesion and  invasiveness of SK-N-AS cells, but not in SH-SY5Y 
human  neuroblastoma  cells.  They  showed  that  10µM  and  20µM  RGZ  decreased  cell 
adhesion over a 24-hour period of time in SK-N-AS cells and that this was through a PPARγ 
independent pathway. Similar effects have been reported in adrenal (Ferruzzi et al 2005) and 
pancreatic (Farrow et al 2003, Galli et al 2004) tumour cells where RGZ inhibits the matrix 
metalloproteinases (MMPs) activity in PPARγ in an independent manner. 
In our experiments, we saw that 100µM RGZ significantly inhibited SK-N-AS cell growth 
over 72 hours, but did not affect cell viability (figure  3.1). We also combined RGZ with 
conventional  chemotherapy  drugs  to  determine  if  the  potency  of  these  agents  could  be 
improved and whether, by combining these agents, lower concentrations of the chemotherapy 
agents could be used, which have considerable  side effects. Before combining  RGZ with 
cisplatin and etoposide, we initially treated SK-N-AS cells with increasing concentrations of 
cisplatin  and  etoposide  alone.  We  found  that,  as  expected,  both  cisplatin  and  etoposide 
inhibited the growth of SK-N-AS cells. However, we did not detect any effect on cell viability 
of  either  cisplatin  or  etoposide,  at  any  of  the  concentrations  used.  Both  cisplatin  and 
etoposide have been reported to induce cell death in neuroblastoma cells (Day et al 2009, 
Lindskog et al 2004) at concentrations similar to those used here. However, it may be that 
higher concentration of drug was required to see the cytotoxic effects of these drugs, so it 
would have been interesting to repeat the dose response curves for cisplatin and etoposide 
using higher concentrations of each drug, as well as using an alternative method of measuring 99 
 
cell death. We did find, however, that combining both cisplatin at 1µM or etoposide at 0.5 
and 1.5µM in the presence of RGZ increased the level of growth inhibition compared to cells 
treated with cisplatin or etoposide alone; although at the highest concentrations of cisplatin 
(5µM)  and  etoposide  (2µM),  no  additive  effect  with  RGZ  was  observed.  It  would  be 
interesting to test the combination of PPARγ ligands with cisplatin and etoposide further and 
determine whether, in vivo, the sensitivity to cisplatin or etoposide had improved by using 
these agents in combination with RGZ. Combinations of fenretinide (4-HPR) and all-trans-
retinoic  acid  with  cisplatin  have  also  been  reported to  enhance  sensitivity  to  cisplatin  in 
cancer cells (Formelli and Cleris 2000).  
Loreto et al. (2007) have also shown that PPARβ/ʴ agonists oleic acid and GW0742 induce 
either cell cycle arrest in the G1 phase and increase neuronal differentiation in SH-N-5YSY 
cells  which  is  a  human  neuroblastoma  cell  line,  inducing  p16
INK4ʱ  levels  and  decreasing 
cyclin D1 levels (Di Loreto et al 2007). Di Loreto and colleagues suggest that both PPARγ 
and PPARβ/ʴ ligands inhibit cell proliferation (Di Loreto et al 2007). It is possible to use dual 
agonists to affect tumour progression and recurrence (Di Loreto et al 2007).  
We also examined the effect of folic acid on neuroblastoma cells and assessed whether folic 
acid  in  combination  with  either  conventional  chemotherapy  agents  or  RGZ  affected  the 
response of neuroblastoma cells to these agents. Methylation is known to play a key role in 
cancer initiation and progression and it has been found that folic acid in the diet is associated 
with a decline in the risk of neuroblastoma (French et al 2003a). In addition, recent studies 
have implicated the enhanced expression of DNMT1 with resistance to chemotherapy drugs 
(Qiu et al 2002a). We found however those different concentrations of folic acid (1, 10 and 
50µM) had no effect on either cell proliferation or cell viability. Neither did the combination 
of folic acid with either RGZ or cisplatin affect or alter the response of cells to these agents. 
However, to be sure that the addition of folic acid to the cells was affecting the methylation 
status or one-carbon metabolism within the cells, it would have been better to have confirmed 
that treatment with folic acid was increasing intracellular concentrations of folic acid, levels 
of DNA methylation and SAM/SAH ratios. In addition, it would be interesting to determine 
the  effect  of  folate  depletion  or  the  effects  of  using  anti-methylating  agents  such  as  the 
inhibitors of DNMT1 or 5-aza-2'-deoxycytidine (Baylin 2004). 
In conclusion, even though chemotherapy drugs have been used a great deal with cancer cells, 
the levels of drug resistance and differences in cell types result in different responses to those 100 
 
drugs. These results, however, suggest that using a combination of agents to both improve 
effect of cell proliferation and differentation and combat drug resistance may prove  more 
promising.  
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Chapter 5 
5.1 Introduction  
More and more research has shown that DNA methylation is correlated with cancer and has 
an effect on the initiation and progression of cancer (Szyf et al 1984). In cancer cells, there is 
a  dramatic  change  in  DNA  methylation  status  and  in  many  cancer  cells  global  DNA 
hypomethylation  has  been  observed.  DNA  hypomethylation  unmasks  transponsons  which 
cause  chromosomal  rearrangements  and  chromosomal  instability.  In  addition  to  global 
hypomethylation  in  cancer  cells,  there  is  also  gene-specific  hypermethylation  of  tumour 
suppressor genes, which  is one mechanism for loss of gene function. Such aberrant DNA 
methylation  is  strongly  associated  with  aggressive  cancers  and  poor  outcome  for  cancer 
patients. DNA methylation patterns have also been shown to change during the process of 
aging, which may be a key contributor. For instance, it has been found that in somatic cells, 
ageing  facilitates  an  increase  in  gene  promoter  methylation.  Therefore,  the  methylation 
changes in ageing may be the first steps in early carcinogenesis (Gilbert 2009). 
Alterations in the expression of the enzymes that bring about DNA methylation have also 
been  observed  in  cancer  cells.  Increased  expression  of  the  maintenance  DNA  methyl 
transferase  I  (DNMT1)  has  been  shown  to  be  strongly  correlated  with  poor  tumour 
differentiation and  frequent DNA  hypermethylation  in  multiple CpG  islands  in  malignant 
cancers (Ehrlich 2002). DNMT1 expression is known to be regulated by a number of factors 
including activator protein 1 (AP-1), E2F1 and Sp1/Sp3 (Yoder et al 1996). Interestingly we 
found a putative PPRE sequence within the promoter of rat DNMT1 (unpublished data from 
Alenad). The potential ability of PPARγ to regulate DNMT1 expression is very interesting as 
this might have implications for cancer progression and also contribute to the anti cancer 
effects of PPARγ and its ligands. Therefore, the aim of this chapter was to investigate the 
regulation of DNMT1 expression by PPARγ.  
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5.2 Results 
5.2.1 Putative PPARγ binding sites in the rat and human DNMT1 promoter 
regions 
To determine whether the human DNMT1 promoter region also contained a potential PPRE 
sequence, the rat and human promoter regions of DNMT1 were aligned and the sequence 
analysed  using  MatInspector  (http://www.genomatix.de/en/index.html).  Both  the  rat  and 
human DNMT1 promoter regions were found to contain potential PPRE sequences (figure 
5.1). 103 
 
                                 Forward          
rat_            G--------TCCTAGAAT------TCACTGTATAGACTTGGCTAGCCTCAAATAGTGATC 1291 
human_          GGAATGTAGTGGTACAATCATGGCTCACTGCA-ACCTCTGCCTCTCCGGTTCAAGTGATC 1354 
                *        *  ** ***      ****** * *    ** **  **      ******* 
 
rat_            TGTCTGCCTCTGCCTCAGTGCAAG---GGATTAAAGGCATGCGCCACTGCTGC---CTGG 1345 
human_          TTCCTGCCTCAACCTCTGGAGTAGTTTGGACTATGGGCACATGCCACAACGACTAGCTAA 1414 
                *  *******  **** *    **   *** **  ****   *****  *  *   **   
 
rat_            GTTTTTTTTTTTTTTTTTTTTTTTTTGGTTCTTTTTTTTGGAGCTGGGGACCGAACCCAG 1405 
human_          TTTTTGTTTTTCTTTTTTTCTTTCTTTCTTTCTTTCTTTTTTTTTTTTTTTGAGATGCAG 1474 
                 **** ***** ******* *** **  **  *** ***     *         *  *** 
 
rat_            GGCCT-TGCGCTTCCTAGGTAAGCGCTCTACCACTGAGCTAAA-----TCCCCAACCCTT 1459 
human_          TTTCTCTATGTTACCTAGGCTGGTCTAAAACTCCTGGGCTCAAGCGATCCTCCCACCCTG 1534 
                   ** *  * * ******   *      **  *** *** **      * ** *****  
 
rat_            TTTTTCTT---TTTTAAAAAGACTGTTTTTAGACCAGGCTGAACACACAGATCCTCCCAC 1516 
human_          GCCTCCCAAAGTGCTGGGATGACAGGCGTGAG-CCACGTGGTGCTTAAAAAAGGCAACAA 1593 
                   * *     *  *   * *** *   * ** *** *  *  *  * * *      **  
                                                              #PPARγ binding site 
rat_            TTCTGCCCCCAGAGTGCTGGGATTAAAAA---CATGGCGCCACAGACTCCACCA---CCT 1570 
human_          AAAACCCCCCACA-CACTGGGTATAGAAGTGGCATGGGCCTCTATACACTGTGAGATTCT 1652 
                     ****** *   *****  ** **    *****  *   * ** *    *    ** 
 
rat_            CTGCCCGACTCAAAAGATCACTTTTTTTAAAAAAAATTGT---GTTTGTGCATGTGAGT- 1626 
human_          TGGTACTAGCTACAAATTCTGTGTATACTCAAGATTTTCTAGAGTAGGTGCAATTACCCC 1712 
                  *  * *   * **  **  * * *    ** *  ** *   **  *****  *      
                                                         #PPARγ binding site 
rat_            GCGGTGCCCATAGAGAC-CAGAAG--AGGGCGTAG-GATCCCCTGGAAGTGGAACTACAA 1682 
human_          GTTTTACAGATGAGGACACAGAGGCTGAGCCGTAGTGACCCACCTAAGGTCGTATAGCCA 1772 
                *   * *  **   *** **** *    * ***** ** ** *   * ** * *   * * 
 
rat_            G-----GGCTTGGAGT--GCCTGGATGTGGGTGCCCTGTGAAAGGGGAGTACTACCTGCT 1735 
human_          GCAAATAGATGGAGGTTGGATTGGAACTGAGGACTTTACTCAAGGG--CTCTCACAAACC 1830 
                *      * * *  **  *  ****  ** *  *  *    *****   *   **   *  
 
rat_            CTCAAGGGCT-------GATCCACCTCT-TCAGGC---AAGGGGGAGGTGAGTG---GCT 1781 
human_          CTTGGGGGCTTCTCGCTGCTTTATCCCCATCACACCTGAAAGAATGAATGAATGAATGCC 1890 
                **   *****       * *  * * *  ***  *   ** *      *** **   **  
 
rat_            CCAGTCACAGTGC--------------------------GGACGAGCCCACTCCAGC-CA 1814 
human_          TCGGGCACCGTGCCCACCTCCCAGCAAACCGTGGAGCTTGGACGAGCCCACTGCTCCGCG 1950 
                 * * *** ****                          ************* *  * *  
 
rat_            GGAGGTGTGGGTGCCTCCGTCCTGCGCATGCGCA------------------CTCCGTTC 1856 
human_          TGGGGGGGGTGTGTGCCCGCCTTGCGCATGCGTGTTCCCTGGGCATGGCCGGCTCCGTTC 2010 
                 * ** * * ***   *** * **********                    ******** 
 
rat_            ---------GGGCATAGCATTGTCTTCCCCCACT-----------CTCTTGCCCTGTG-- 1894 
human_          CATCCTTCTGCACAGGGTATCGCCTCTCTCCGTTTGGTACATCCCCTCCTCCCCCACGCC 2070 
                         *  **  * ** * **  * **  *           *** * ***   *   
 
rat_            ----------TGGTACATGCTGCTTCCGCTTGCGCCGCCCCCTCCCAATTGGTTTCCGCG 1944 
human_          CGGACTGGGGTGGTAGACGCCGCCTCCGCT--CATCGCCCC-TCCCCATCGGTTTCCGCG 2127 
                          ***** * ** ** ******  *  ****** **** ** ********** 
                                                                       Reverse 
rat_            CGCGCGAAAAAGCCGGGGT-CTCGTTCAGA-GCTGTCCTGTCGTCTGCAACCTGCAAGAT 2002 
human_          CG-----AAAAGCCGGGGCGCCTGCGCTGCCGCCGCCGCGTCTGCTGAAGCCTCCGAGAT 2182 
                **     ***********  *  *  * *  ** * *  ***  *** * *** * **** 
 
rat_            GCCAGCACGAACAGCTCCAGCCCGAGTGCCTGCACTTGCCTCCCCGGCAGGCTCGCTCCC 2062 
human_          GCCGGCGCGTACCGCCCCAGCCCGGGTGCCCACACTGGCCGTCCCGGCCATCTC------ 2236 
                *** ** ** ** ** ******** *****  **** ***  ******   ***       
 
rat_            CG 2064 
human_          -- 
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Figure 5.1. Alignment of rat and human DNMT1 promoter regions. The nucleotide bases 
in  the  DNMT1  sequence  of  two  species.  The  alignment  sequence  includes  the  PPARγ 
putative  binding  site  in  the  rat  DNMT1  promoter  region  (pink)  and  the  human  DNMT1 
promoter region (yellow). The primers used to clone the rat Dnmt1 promoter forward, and 
reverse are shown in blue.  
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5.2.2  Endogenous  DNMT1  mRNA  expression  is  negatively  regulated  by 
rosiglitazone 
To determine whether PPARγ may regulate endogenous DNMT1 expression, SK-N-AS cells 
were treated with increasing concentrations of the PPARγ ligand, RGZ for 24 and 72 hours. 
After 24 hours, there was a decrease in DNMT1 mRNA expression at 5, 50 and 100µM RGZ. 
After 72 hours, although there was an increase in expression at 5µM, however, at 50 and 
100µM RGZ, there was a decrease in DNMT1 expression. This suggests that the PPARγ 
ligand RGZ induces the down regulation of DNMT1 expression (figure 5.2).   
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Figure 5.2. The expression of DNA methyltransferase 1 with increasing concentration of 
rosiglitazone over 24 and 72 hours. The expression of DNMT1 was detected in SK-N-AS 
cells  by real-time PCR (n=1). There was an overall decrease  in DNMT1 expression with 
increasing RGZ concentration at both 24 and 72 hours. 106 
 
5.2.3 PPARγ represses DNMT1 promoter activity at 24 hours and 48 hours 
To begin to determine whether PPARγ directly regulates DNMT1 expression, a construct 
(DNMT1-Luc)  containing  the  promoter  region  of  rat  DNMT1  which  had  been  cloned 
upstream of the luciferase reporter gene in the vector pGL3 basic (Kind gift of Amal Alenad) 
was transfected into SK-N-AS cells with increasing concentrations of an expression vector 
containing a full length cDNA clone of PPARγ. The rat DNMT1 promoter region included 
the PPARγ putative binding site, and encompasses the region from -751bp to +15bp (figure 
5.3A). 
The experiment is designed for trasnfection with the final  volume of 300ng plasmid. The 
amount of  PPARγ  and  PPARγ  DN  has  transfected  either  100ng  or  200ng.  However, the 
amount of DNMT1 has remained constant at 100ng for the entire experiment. The results 
showed that the addition of increasing amounts of the PPARγ expression vector (100 and 
200ng) into cells transfected with the DNMT1-Luc construct led to a decrease in luciferase 
activity,  suggesting  that  PPARγ  can  repress  DNMT1  promoter  activity  (figure  5.3B). 
Moreover, as we can see in the column of number 5 of figure 5.3B, even though transfection 
of  the  DNMT1-Luc  construct  with  increasing  amounts  of  the  PPARγ  dominant  negative 
expression vector (200ng) led to an small increase in DNMT1 promoter activity, consistent 
with  previous  findings,  that  wild-type  PPARγ  inhibits  DNMT1  promoter  activity  (figure 
5.3B).  107 
 
A. 
Rat DNMT1 promoter region 
>8 dna:chromosome chromosome:RGSC3.4:8:19926966:19974256:-1 
 
                              Forward  
AGGGTTTCTCTGTATAGCCCTGGCTGTCCTAGAATTCACTGTATAGACTTGGCTAGCCTC 
AAATAGTGATCTGTCTGCCTCTGCCTCAGTGCAAGGGATTAAAGGCATGCGCCACTGCTG 
CCTGGGTTTTTTTTTTTTTTTTTTTTTTTTTGGTTCTTTTTTTTGGAGCTGGGGACCGAA 
CCCAGGGCCTTGCGCTTCCTAGGTAAGCGCTCTACCACTGAGCTAAATCCCCAACCCTTT 
TTTTCTTTTTTAAAAAGACTGTTTTTAGACCAGGCTGAACACACAGATCCTCCCACTTCT 
                                         #PPARγ binding site 
GCCCCCAGAGTGCTGGGATTAAAAACATGGCGCCACAGACTCCACCACCTCTGCCCGACT 
CAAAAGATCACTTTTTTTAAAAAAAATTGTGTTTGTGCATGTGAGTGCGGTGCCCATAGA 
GACCAGAAGAGGGCGTAGGATCCCCTGGAAGTGGAACTACAAGGGCTTGGAGTGCCTGGA 
TGTGGGTGCCCTGTGAAAGGGGAGTACTACCTGCTCTCAAGGGCTGATCCACCTCTTCAG 
GCAAGGGGGAGGTGAGTGGCTCCAGTCACAGTGCGGACGAGCCCACTCCAGCCAGGAGGT 
GTGGGTGCCTCCGTCCTGCGCATGCGCACTCCGTTCGGGCATAGCATTGTCTTCCCCCAC 
TCTCTTGCCCTGTGTGGTACATGCTGCTTCCGCTTGCGCCGCCCCCTCCCAATTGGTTTC 
                                       +1(Transcription start site) 
CGCGCGCGCGAAAAAGCCGGGGTCTCGTTCAGAGCTGTCCTGTCGTCTGCAACCTGCAAG 
Translation start site 
ATGCCAGCACGAACAGCTCCAGCCCGAGTGCCTGCACTTGCCTCCCCGGCAGGCTCGCTC 
         Reverse  
 
 
 
B. 
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Figure 5.3 PPARγ negatively regulates rat DNMT1 promoter activity at 24 hours. A. 
Rat DNMT1 promoter region. The primers (forward and reverse (blue)) and PPARγ binding 
site (pink) are shown. The transcription start site starts from guanine (G) (red). The ATG is 
shown in bold.  B. SK-N-AS cells were plated out in 24-well dishes at 2.5x10
4 cells per well 
and  transfected  with  either  the  empty  pcDNA  3.1  expression  vector,  PPARγ1  expression 
vector or the PPARγ dominant negative expression plasmid together with the rat DNMT1 
promoter reporter plasmid. Cells were harvested after 24 hours and luciferase activity of the 
rat DNMT1 promoter luciferase reporter in the cells (normalising its activity of concentration 
protein 1µg/µl) measured. This experiment represents three independent experiments ± s.d. 
Statistics were calculated using a Student’s t-test. 
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5.2.4  Both  natural  and  synthetic  PPARγ  ligands  repress  rat  DNMT1 
promoter activity in SK-N-AS cells at 48 hours 
Having shown that transfection of a PPARγ expression vector leads to the repression of rat 
DNMT1 promoter activity at 24 hours, we then examined whether addition of PPARγ ligands 
would also lead to the repression of DNMT1 promoter activity at 48 hours. To investigate 
this, cells were transfected with an increasing amount of PPARγ expression vector together 
with DNMT1 reporter construct DNMT1-Luc, in the presence or absence of one or more of 
the PPARγ ligand, RGZ or 15dPGJ2. We found that PPARγ at 200µg repressed DNMT1 
promoter  activity  significantly.  This  repression  was  further  enhanced  by  the  treatment  of 
transfected cells with either 15dPGJ2 (P=0.01) or RGZ (P=0.003). 110 
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Figure 5.4. The effect of 15dPGJ2 and rosiglitazone on DNMT1 promoter activity at 48 
hours. SK-N-AS cells were plated out at 2.5x10
4 cell density and transfected with either an 
empty expression vector or PPARγ expression plasmid together with the rat  DNMT1-Luc 
reporter  plasmid.  Then  after  48  hours,  the  cells  were  treated  for  24  hours  with  10µM 
15dPGJ2  or  50µM  RGZ  and  luciferase  activity  measured  by  TD-20/20  luminometer  and 
normalised by protein concentration (1µg/µl). This represents three independent experiments 
± s.d. Statistics were calculated using a Student’s t-test and showed significant difference in 
the  level  of  luciferase  activity  of  the  DNMT1  promoter  luciferase  activity  (*P<0.05  and 
**P<0.01).  
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5.2.5 Does deletion of the putative PPRE abolish repression by PPARγ? 
To  determine  whether the  putative  PPRE  located  at  -336 to -359  base  pair  mediated the 
repression by PPAR on rat DNMT1 promoter activity, a shorter DNMT1 promoter construct 
was made, but lacking the PPRE site. The rat DNMT1-Luc reporter plasmid was digested 
from restriction enzymes BamHI and HindIII to create a DNMT1 promoter fragment of 356 
base pair and religated into pGL3basic. Unfortunately, because of time constraints, we were 
unable to test whether this construct responded to PPARγ (figure 5.5). 112 
 
A. 
                               Forward 
AGGGTTTCTCTGTATAGCCCTGGCTGTCCTAGAATTCACTGTATAGACTTGGCTAGCCTC 
AAATAGTGATCTGTCTGCCTCTGCCTCAGTGCAAGGGATTAAAGGCATGCGCCACTGCTG 
CCTGGGTTTTTTTTTTTTTTTTTTTTTTTTTGGTTCTTTTTTTTGGAGCTGGGGACCGAA 
CCCAGGGCCTTGCGCTTCCTAGGTAAGCGCTCTACCACTGAGCTAAATCCCCAACCCTTT 
TTTTCTTTTTTAAAAAGACTGTTTTTAGACCAGGCTGAACACACAGATCCTCCCACTTCT 
                                         #PPARγ binding site 
GCCCCCAGAGTGCTGGGATTAAAAACATGGCGCCACAGACTCCACCACCTCTGCCCGACT 
CAAAAGATCACTTTTTTTAAAAAAAATTGTGTTTGTGCATGTGAGTGCGGTGCCCATAGA 
 
GACCAGAAGAGGGCGTAGGA[TCCCCTGGAAGTGGAACTACAAGGGCTTGGAGTGCCTGGA 
TGTGGGTGCCCTGTGAAAGGGGAGTACTACCTGCTCTCAAGGGCTGATCCACCTCTTCAG 
GCAAGGGGGAGGTGAGTGGCTCCAGTCACAGTGCGGACGAGCCCACTCCAGCCAGGAGGT 
GTGGGTGCCTCCGTCCTGCGCATGCGCACTCCGTTCGGGCATAGCATTGTCTTCCCCCAC 
TCTCTTGCCCTGTGTGGTACATGCTGCTTCCGCTTGCGCCGCCCCCTCCCAATTGGTTTC 
                                       +1(Transcription start site) 
CGCGCGCGCGAAAAAGCCGGGGTCTCGTTCAGAGCTGTCCTGTCGTCTGCAACCTGCAAG 
+83 Translation start site 
ATGCCAGCACGAACAGCTC] HindIII 
Reverse  
 
BamHI 
 356bp                  
 (Cloning into pGL3 
vector)   
 
B. 
BamHI
Marker
(bp)
Uncut  HindIII HindIII
75
200
300
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Figure 5.5. Rat DNMT1-Luc reporter plasmid digested with restriction enzymes. A. The 
sequence of the rat DNMT1 promoter region indicating the location of the PPARγ binding 
site  and  restriction  enzymes  sites  used  to  create  a  truncated  promoter  fragment.  B.  Rat 
DNMT1-Luc reporter plasmid digested with Bam HI with Hind III (lane 3). DNA product is 
356 base pairs. Cutting plasmid DNA was extracted from the agarose gel ready to clone the 
insert to the pGL3 luciferase reporter vector.  113 
 
 5.3 Discussion  
There is growing evidence that aberrant methylation plays a key role in cancer initiation and 
progression (Plass 2002). Hypermethylation of the gene promoter leads to gene inactivation 
of  the  corresponding  genes,  because  methylated  cytosines  are  recognised  and  bound  by 
methyl  binding  proteins  such  as  MeCP2,  which  in  turns  recruits  HDACs  (Taby  and  Issa 
2010).  Methylated-associated  gene  silencing  in  various  genes  has  been  demonstrated, 
including tumour suppressor genes (p14
ARF and p16
INK4ʱ). Gene hypermethylation can be a 
target for therapeutic invention by hypomethylating agents. In neuroblastoma, drug resistance 
to conventional chemotherapy drugs has also been linked to altered DNA methylation. It has 
been  shown  that the  expression  of  DNMT1  is  correlated  with  drug  resistance  (Qiu  et  al 
2002b). Qiu’s (2002) group has reported that in drug-resistant cells, the activity of DNMT1 
enzyme has increased 33% compared to the non-drug-resistant cells. Moreover, the protein 
expression of DNMT1 is significantly increased in drug-resistant cells. However, this may 
mean that the loss of the function of cell growth control or overexpression of DNMT1 may be 
silencing  the  tumour  suppressor  gene  because  of  gene  methylation  (Qiu  et  al  2002b). 
Therefore, it is important to understand how DNMT1 can be regulated. 
In this chapter, we show for the first time that PPARγ can negatively regulate rat DNMT1 
promoter activity (figure 5.3). There is no concentration dependent repression of DNMT1 in 
the presence of increasing concentration of PPARγ as DNMT1 expression was decreased to a 
similar  extent  with  both  100ng  and  200ng  PPARγ  at  24  hours.  To  see  a  concentration 
dependent decrease in DNMT1 is observed lower concentrations of PPARγ may be needed. 
Moreover, PPARγ ligands (15dPGJ2 and RGZ) repress DNMT1 promoter activity (figure 
5.4). This suggests that PPARγ ligands may, in addition to their anti-growth properties, also 
affect  DNA  methylation  levels  in  cancer  cells.  The  average  luciferase  activity  in  the 
experiments where cells were treated for 24hrs as opposed to 48 hours was much higher, 
which could be due to differences in the treatment period. A decrease in DNMT1 expression 
in  response  to  200µg  of  PPARγ  was  again  observed  (figure  5.4).  It  also  suggests  that 
combining PPARγ  ligands with conventional chemotherapy agents  might be beneficial  in 
terms of reducing drug resistance. For those results, combining epigenetic treatment (5-aza-
2'-deoxycytidine) and TZDs (rosiglitazone) might have a synergistic effect on cancer because 
overexpression DNMT1 has been implicated in drug resistance (Qiu et al 2002b). Therefore, 114 
 
it may prove possible to combine epigenetic treatments, such as 5-aza-2'-deoxycytidine and 
TZDs, for a synergistic effect on cancer in the future.  
In future studies, our group will focus on how PPARγ inhibits DNMT1 in specific regions; 
therefore, firstly, we were going to prepare the rat DNMT1 promoter region without PPARγ 
putative binding site and clone it to the pGL3 reporter plasmid to demonstrate whether the 
PPARγ putative binding region can affect the transcription of rat DNMT1 in neuroblastoma 
SK-N-AS cells (figure 5.5). Secondly, in order to understand whether PPARγ ligand directly 
or indirectly inhibits DNMT1 mRNA expression, previous results have shown that RGZ may 
increase DNMT1 mRNA expression; therefore, we will use cycloheximide which  inhibits 
protein synthesis in cytoplasm.  115 
 
Chapter 6 
Final Conclusions and Discussion 
The aim of this study was to investigate the role of PPARγ in neuroblastoma SK-N-AS cells to 
establish whether PPARγ acts as a tumour suppressor gene in neuroblastoma cells. PPARγ is 
present in neuroblastoma cell lines (Servidei et al 2004) and also in primary neuroblastoma 
cell  cultures  (Grommes  et  al  2004b).  In  order  to  understand  the  action  of  PPARs  on 
neuroblastoma cells, most studies have investigated the influence of their natural or synthetic 
ligands on cell proliferation, death and differentiation.  It has been shown that the natural 
PPARγ agonist (15dPGJ2) inhibits cellular growth, decreases cellular viability and induces 
apoptosis in human neuroblastoma cells in vitro (Han et al 2001a, Han et al 2001c, Rodway 
et  al  2004a,  Servidei  et  al  2004).  In  addition,  it  has  been  shown  that  treatment  of 
neuroblastoma  cells  with  PPARγ  ligands  leads  to  the  induction  of  the  cyclin-dependent 
kinase inhibitor (CDKI), involving p21
CIP, p27 and p16
INK4ʱ (Chang and Szabo 2000, Han et 
al 2004, Lapillonne et al 2003, Wang et al 2006b, Yang et al 2005, Yoshizawa et al 2002, 
Yoshizumi et al 2004). However, several papers have demonstrated that the effect is based on 
the PPARγ independent pathway (Giri et al 2004). 
High levels of PPARγ have been reported to be associated with low stage neuroblastoma with 
a well differentiated phenotype, while low levels of PPARγ have been associated with high 
stage  poorly  differentiated  neuroblastoma.  We  have  shown  that  increasing  the  level  of 
PPARγ expression and activity in  neuroblastoma cells leads to a decrease in cell growth, 
although no effect on cell viability or differentiation was seen. It would have been interesting 
to  have  examined  the  expression  of  proteins  associated  with  a  mature  differentiated 
phenotype, or to have stably transfected cells with the PPARγ expression vector, so that cells 
could  be  left  for  a  longer  period  of  time  before  examining  for  signs  of  morphological 
differentiation.  
We did however see an increase in the expression of p14
ARF in cells overexpressing PPARγ. 
Moreover, analysis of the promoter region of p14
ARF found a PPRE sequence, increasing the 
possibility that PPARγ may directly regulate p14
ARF expression. Interestingly bioinformatic 
analysis of the promoter regions of p21
CIP and p16
INK4ʱ also revealed the presence of putative 
PPREs, suggesting that these cell cycle inhibitors may also be directly regulated by PPARγ 116 
 
and their induction may play a role in the decrease in cell growth induced by higher levels of 
PPARγ and in the inhibition of cell proliferation induced by PPARγ ligands.  
To  determine  whether  combining  PPARγ  ligands  with  conventional  chemotherapy  agents 
may improve potency and allow a lower concentration of the chemotherapy agent to be used, 
we treated cells with a combination of RGZ and either cisplatin or etoposide. We found that 
the combination of RGZ with moderate concentrations of either cisplatin or etoposide did 
enhance  the  growth  inhibitory  effects  of  the  chemotherapy  agents;  although  at  higher 
concentrations of cisplatin and etoposide, no additive effect was seen. In our experiments, 
cisplatin and etoposide at the concentrations used had very little effect on cell viability either 
alone or in combination with RGZ. It may be that higher concentrations of these agents are 
required to induce cell death. We used a range of concentrations which were shown in the 
literature to induce growth inhibition and cell death in other cancer cell lines, such as small 
cell  lung  cancer  (Jordan  and  Carmo-Fonseca  2000, Kurup  and  Hanna  2004, Zamble  and 
Lippard 1995); however, it has been reported that some cells, such as  SH-SY5Y cells, are 
more resistance to these agents because endogenous expression of nerve growth factor (TRK-
B)  and  its  ligand-brain-derived  neurotrophic  factor  (BDNF)  (Ho  et  al  2002).  With  a 
combination of RGZ and etoposide, however, a decrease in cell viability was observed with 
up to 50% decrease in cell viability observed with 2µM etoposide and 100µM RGZ.  
As there is  increasing evidence that methylation plays a key role  in cancer initiation and 
progression, we also examined the effect of folic acid supplementation on the response of 
cells  to  either  RGZ  or  the  conventional  chemotherapy  agents,  cisplatin  and  etoposide. 
However, we found that folic acid had little effect alone or in combination with either RGZ, 
or cisplatin or etoposide. Further experiments are needed to examine the impact methylation 
has  on  these  agents  either  by  carrying  out  a  dose-response  experiment  over  a  larger 
concentration range in folate-depleted medium or by using anti methylating agents, such as 5-
aza-2'-deoxycytidine, to affect levels of methylation within the cells.  
We  did  however  find  that  PPARγ  negatively  regulates  DNMT1  expression.  DNA 
methyltransferase 1 (DNMT1) maintains DNA methylation patterns during replication and is 
overexpressed in many human cancers (Luczak and Jagodzinski 2006). Increased DNMT1 
(mRNA and protein) in various cancer types is correlated with hypermethylation in the CpG 
island  on  the  cyclin-dependent  kinase  inhibitors  promoter  regions,  such  as  p16
INK4ʱ, 
mismatch repair gene (MLH1), retinoblastoma 1 (Rb1), TIMP metallopeptidase inhibitor 3 117 
 
(TIMP3) and other tumour suppressor genes (Sato et al 2002). We have found that PPARγ 
can  negatively  regulate  DNMT1  expression.  We  have  shown  that  PPARγ  ligands  down-
regulate  endogenous  DNMT1  expression  and  that  either  overexpression  of  PPARγ  or 
addition  of  PPARγ  ligands  represses  DNMT1  promoter  activity.  It  would  have  been 
interesting to determine whether PPARγ directly affects DNMT1 expression by i) mutation 
and/or deletion the putative PPREs within the DNMT1 promoter and analysing the effect of 
PPARγ  on the  mutated  construct,  and  by  ii)  treating  cells  with  both  a  PPAR  ligand  and 
cycloheximide  to  block  protein  synthesis  to  determine  whether  a  decrease  in  DNMT1 
expression is still observed.  
The ability of PPARγ to potentially regulate DNMT1 is very important and may contribute to 
the anti-cancer effects of PPARγ and its ligands. DNMT1 has been implicated not only in the 
progression  of  cancer  but  also  in  the  development  of  drug  resistance  to  conventional 
chemotherapy agents. Treatment of PPARγ ligands together with conventional chemotherapy 
agents might therefore lessen the development of drug resistance. This is potentially a very 
important avenue to follow up. The finding that PPARγ can regulate DNMT1 will also help 
us to understand the role of PPARγ in the treatment of neuroblastoma and understand the link 
between methylation and PPARγ. 
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